
Neuron

Astrocyte Unfolded Protein Response Induces a Specific Reactivity State that Causes Non-Cell-Autonomous Neuronal Degeneration

Graphical Abstract



Authors

Heather L. Smith, Oliver J. Freeman, Adrian J. Butcher, ..., David H. Rowitch, Robin J.M. Franklin, Giovanna R. Mallucci

Correspondence

gm522@cam.ac.uk

In Brief

Dysregulation of UPR signaling in neurons is a key mediator of neurodegeneration. Smith et al. show that UPR dysregulation in astrocytes impairs their ability to support synapses; modulating astrocytic UPR signaling prevents neuronal loss and increases survival in prion-diseased mice.

Highlights

- PERK-elF2α signaling in astrocytes generates a distinct "UPR"-reactivity state
- UPR-reactive astrocytes have an altered secretome, with reduced synaptogenic factors
- UPR-reactive astrocytes fail to support synaptogenesis in vitro
- Targeting the astrocytic UPR prevents synapse and neuronal loss in prion-diseased mice

Smith et al., 2020, Neuron *105*, 855–866 March 4, 2020 © 2019 The Authors. Published by Elsevier Inc. https://doi.org/10.1016/j.neuron.2019.12.014



Astrocyte Unfolded Protein Response Induces a Specific Reactivity State that Causes Non-Cell-Autonomous Neuronal Degeneration

Heather L. Smith,¹ Oliver J. Freeman,¹ Adrian J. Butcher,¹ Staffan Holmqvist,² Ibrahim Humoud,¹ Tobias Schätzl,¹ Daniel T. Hughes,¹ Nicholas C. Verity,³ Dean P. Swinden,¹ Joseph Hayes,¹ Lis de Weerd,¹ David H. Rowitch,² Robin J.M. Franklin,² and Giovanna R. Mallucci^{1,4,*}

¹Department of Clinical Neurosciences and UK Dementia Research Institute at the University of Cambridge, Island Research Building, Cambridge Biomedical Campus, Cambridge, UK

²Wellcome-MRC Cambridge Stem Cell Institute, Jeffrey Cheah Biomedical Centre, Cambridge Biomedical Campus, Cambridge, UK ³MRC Toxicology Unit, Hodgkin Building, Leicester, UK

⁴Lead Contact

*Correspondence: gm522@cam.ac.uk

https://doi.org/10.1016/j.neuron.2019.12.014


SUMMARY

Recent interest in astrocyte activation states has raised the fundamental question of how these cells, normally essential for synapse and neuronal maintenance, become pathogenic. Here, we show that activation of the unfolded protein response (UPR), specifically phosphorylated protein kinase R-like endoplasmic reticulum (ER) kinase (PERK-P) signaling—a pathway that is widely dysregulated in neurodegenerative diseases-generates a distinct reactivity state in astrocytes that alters the astrocytic secretome, leading to loss of synaptogenic function in vitro. Further, we establish that the same PERK-P-dependent astrocyte reactivity state is harmful to neurons in vivo in mice with prion neurodegeneration. Critically, targeting this signaling exclusively in astrocytes during prion disease is alone sufficient to prevent neuronal loss and significantly prolongs survival. Thus, the astrocyte reactivity state resulting from UPR over-activation is a distinct pathogenic mechanism that can by itself be effectively targeted for neuroprotection.

INTRODUCTION

The buildup of misfolded proteins, characteristic of many neurodegenerative diseases, is a cellular stress that results in activation of the unfolded protein response (UPR), a signaling cascade that aims to restore protein homeostasis (Ron and Walter, 2007). One branch of the UPR, mediated by phosphorylation of protein kinase R-like ER kinase (PERK), leads to the transient shutdown of protein synthesis through phosphorylation of the α subunit of eukaryotic initiation factor 2 (eIF2 α) (Figure 1A). In several mouse models of neurodegeneration, chronic PERK-eIF2 α -P signaling results in the sustained reduction in global protein synthesis rates, leading to synaptic failure and neuronal loss (Moreno et al., 2012; Radford et al., 2015). Restoration of translation rates in neurons through genetic or pharmacological modulation of PERK-elF2 α -P signaling restores memory and synapse function (Costa-Mattioli et al., 2007; Ma et al., 2013; Sidrauski et al., 2013) and is profoundly neuroprotective in these models (Celardo et al., 2016; Grande et al., 2018; Halliday et al., 2015, 2017; Kim et al., 2014; Mercado et al., 2018; Moreno et al., 2012, 2013; Radford et al., 2015). The pathway has become an area of intense interest for the treatment of human neurodegenerative disorders, where increased levels of PERK-P and elF2 α -P occur in association with misfolded protein accumulation in Alzheimer's and Parkinson's diseases and related disorders (Hoozemans et al., 2005, 2007, 2009; Smith and Mallucci, 2016; Stutzbach et al., 2013).

Although the neuronal, cell-autonomous effects of dysregulated PERK signaling in neurodegeneration are relatively well understood, the role of astrocytic UPR activation in disease is unknown. Astrocytes are key modulators of synaptic structure and function (Allen et al., 2012; Christopherson et al., 2005; Chung et al., 2013; Kucukdereli et al., 2011), and their activation to a "reactive" state is a common feature of neurodegenerative disorders. Recent observations describe "neurotoxic" and "neuroprotective" reactivity states (Liddelow et al., 2017; Zamanian et al., 2012). However, the mechanisms driving astrocyte reactivity during disease and how this impacts on function and pathogenesis remain unclear. In this study, we show that chronic PERK-eIF2a signaling in astrocytes drives a distinct pathogenic reactivity state both in vitro and in vivo. This state, which we term "UPR" reactive, is characterized by an astrocytic secretome devoid of synaptogenic properties. It is reversed by PERK inhibition, which restores synaptogenesis in vitro. Critically, in vivo, modulation of astrocytic PERK-eIF2a signaling in mice with prion disease is profoundly neuroprotective, abrogating clinical signs and prolonging survival, despite ongoing neuronal PERK activation. The pathogenic role of PERK over-activation therefore has a significant, non-cell-autonomous component, generating a distinct reactivity state in astrocytes principally through loss of synaptotrophic function; this provides multiple new targets for



(legend on next page)

restoring synapses and neuroprotection in neurodegenerative diseases with PERK pathway dysregulation.

RESULTS

Chronic PERK Branch Activation Drives a Distinct UPR-Reactivity Profile in Primary Cultured Astrocytes

We first confirmed PERK-elF2a signaling (Figure 1A) in astrocytes in vitro and characterized its temporal profile. Primary astrocytes, cultured from wild-type mice, were treated with the ER stressors thapsigargin (Tg) or tunicamycin (Tm) for 2, 6, or 24 h. PERK activation occurred following 2 h of Tg treatment, with significantly increased levels of phosphorylated PERK (PERK-P) and phosphorylated eIF2 α (eIF2 α -P) at this time point (Figure 1B), consistent with previous reports (Guthrie et al., 2016; Sprenkle et al., 2019). This corresponded with an 88% reduction in global protein synthesis rates at 2 h as a result of rising eIF2a-P levels (Figure 1C). Elevated levels of the downstream markers of elF2a-P signaling, ATF4 and GADD34, were found after 6 and 24 h of Tg treatment, respectively (Figure 1B). Tm, which activates the UPR through a different mechanism to Tg, drove a similar temporal pattern of PERK-elF2a signaling (Figures S1B–S1E). Thus, primary cultured astrocytes exhibit a typical PERK-pathway response to ER stressors.

Next, we asked whether PERK signaling affects astrocyte reactivity in vitro. We assessed the expression levels of a selection of astrocyte reactivity markers, including "pan," "A1," and "A2" markers (Liddelow et al., 2017; Zamanian et al., 2012), following Tg treatment. The A1 reactivity state, described in response to a peripheral inflammatory stimulus, is proposed to be neurotoxic in vitro, whereas the A2 reactivity state, described in response to ischemia, is proposed to be neuroprotective (Liddelow et al., 2017; Zamanian et al., 2012). By 24 h of Tg treatment, the pan-reactive markers Cxcl10, Lcn2, and Vim and the A1 marker C3 were significantly elevated, with 107-fold, 17-fold, 1.8-fold, and 8-fold increases in mRNA levels, respectively (Figure 1E). In contrast, Ggta1 and Serping1 (also A1 markers) were significantly reduced, as were Cd109, Emp1 (A2 markers), and the pan-reactive marker, Serpina3n, with 47%, 81%, 90%, 60%, and 52% reductions in transcript levels, respectively (Figure 1E). Tm treatment induced a similar reactivity profile at 24 h (Figure S1H). Only Emp1 and S100a10 transcript levels differed in the profiles generated by the two ER stressors. Critically, the small molecule GSK2606414, a potent inhibitor of PERK kinase signaling (Axten et al., 2012), prevented the Tg-induced rise in eIF2α-P, ATF4, and GADD34 (Figures 1G and 1H) and, in parallel, significantly reduced the changes to the

reactivity profile when co-administered with Tg (Figure 1I) or Tm (Figure S1H), blunting the increase in Cxcl10, Lcn2, and Vim. Trazodone, a drug that acts downstream of eIF2α-P to reverse PERK-elF2 α -P signaling (Halliday et al., 2017), also reduced the elevated expression of Cxcl10, Lcn2, and Vim, as well as C3, on Tg treatment (Figure S1I). To exclude any off-target effects of GSK2606414 (Mahameed et al., 2019; Rojas-Rivera et al., 2017), we genetically modulated PERK-elF2a signaling using small interfering RNA (siRNA) targeting PERK expression. A 73% knockdown of PERK expression significantly reduced the levels of elF2 α -P on Tg treatment and, crucially, lowered C3, Cxcl10, Lcn2, and Vim, with 61%, 51%, 82%, and 60% reductions in transcript levels, respectively (Figure S2). Thus, PERK signaling is the primary mediator of a distinct astrocytic reactivity profile in vitro (Figure 1F). We term these astrocytes UPR reactive.

UPR-Reactive Astrocytes Fail to Support Synapses In Vitro due to an Altered Secretome

We next tested for functional effects of the PERK-mediated changes to the astrocyte reactivity state. Astrocytes and astrocyte-conditioned media (ACM) have marked trophic effects on synaptogenesis in primary neuronal cultures (Allen et al., 2012; Christopherson et al., 2005; Ullian et al., 2001). We therefore assessed the synaptogenic properties of conditioned media from UPR-reactive astrocytes (Figure 2A). ACM from vehicle-treated astrocytes significantly increased the synaptic density of primary hippocampal neurons by 1.65-fold (Figures 2B and 2C), consistent with previous reports (Allen et al., 2012). In contrast, ACM from Tq-treated astrocytes had no effect on synapse number (Figures 2B and 2C). PERK inhibition restored the synaptogenic properties of the ACM, with ACM derived from GSK2606414treated Tg-stressed astrocytes significantly increasing synapse number by 1.47-fold (Figures 2B and 2C). Thus, PERK activation reduces the synaptogenic function of astrocytes as a result of the altered UPR-reactivity state.

To better understand the mechanisms underlying the loss of astrocytic synaptotrophism upon chronic PERK activation, we compared the secretome of vehicle and Tg-treated astrocytes using unbiased liquid chromatography/mass spectrometry (LC/ MS) analysis. Conditioned media from vehicle-treated astrocytes contained an array of proteins essential for synapse maintenance; constituents of the extracellular matrix, such as collagen, fibronectin, and glypican-4, a key synaptogenic factor (Allen et al., 2012), were particularly abundant (Figure 3A; see Table S1 for full list). The abundance of proteins in the secretome was markedly altered by Tg treatment, with 34 out of the

Figure 1. PERK-eIF2α Signaling Induces a Reactive Phenotype in Primary Cultured Astrocytes

(H) Western blots quantified.

⁽A) Schematic of the PERK branch of the UPR, including the sites of action of the PERK branch inhibitors, GSK2606414 and trazodone.

⁽B) Western blots showing PERK-eIF2α signaling in primary astrocytes treated with 300 nM thapsigargin (Tg) for 2, 6, or 24 h.

⁽C) Primary astrocytes show reduced protein synthesis rates in the presence of Tg, as measured by the incorporation of puromycin into nascent proteins.


⁽D) Quantification of western blots.

⁽E) qPCR analysis of astrocyte reactivity markers revealed an altered profile on Tg treatment.

⁽F) Astrocyte reactivity markers that characterize the UPR-reactive profile.

⁽G) PERK-eIF2a signaling is significantly reduced in primary astrocytes cultured in the presence of Tg and 5 μ M GSK2606414.

⁽I) GSK2606414 significantly blunts the reactivity profile of Tg-stressed astrocytes. All bar graphs show mean \pm SEM. *p < 0.05; **p < 0.01; ***p < 0.001; one-way ANOVA. n = 3 biological replicates.





(A) Schematic illustrating the generation of astrocyte-conditioned media (ACM). Primary astrocytes were treated with vehicle, 300 nM Tg, or 300 nM Tg and 5 μM GSK2606414. Astrocytes were washed 24 h post-treatment and incubated with fresh neuron media for a further 24 h. Conditioned media were transferred to primary hippocampal neurons at 18 days *in vitro* (DIV).

(B) Representative images of primary hippocampal neurons grown without ACM or with vehicle, Tg, or Tg and GSK2606414 ACM. Neurons were immunostained with the pre-synaptic marker, synaptophysin (magenta) and the post-synaptic marker, PSD-95 (green). Arrows highlight co-localized synaptophysin and PSD-95 puncta. Scale bars, (a) 25 μm; (b–d) 10 μm.

(C) Relative number of synapses normalized to the no ACM condition. Tg ACM failed to promote synaptogenesis, whereas Tg and GSK2606414 ACM retained its synaptogenic properties. 10 neurons were counted per condition, per biological replicate (n = 3). Bar graph shows mean normalized synapse number \pm SEM. **p < 0.01; ***p < 0.001; n.s., non-significant; one-way ANOVA.

127 proteins detected showing at least a 1.3-fold reduction in spectral counts compared to the secretome of vehicle-treated astrocytes (Figures 3A and 3B). KEGG (Kyoto Encyclopedia of Gene and Genomes) and Gene Ontology analysis revealed that extracellular matrix and cell adhesion pathways were most significantly affected by Tg treatment (p = 6.9×10^{-7} and 4.6×10^{-5} , respectively; Figure 3C). Downregulation of these

pathways generally, and of the levels of collagen, fibronectin, and glypican-4, specifically, likely explains the loss of synaptotrophic support from UPR-reactive astrocytes. Interestingly, 41/127 (32%) proteins showed a 1.3-fold or greater increase in spectral counts on Tg treatment (Figure 3B; Table S1). These proteins were largely chaperones involved in protein folding and processing in the ER, consistent with UPR activation, and

b) PSD-95

d) merge

c) synaptophysin




Figure 3. UPR-Reactive Astrocytes Have an Altered Secretome

The proteome of conditioned media from vehicle-, Tg-, or Tg and GSK2606414-treated astrocytes was analyzed by LC/MS.

(A) Heatmap showing normalized spectral counts of the 25 most abundant proteins detected in the conditioned media of vehicle-treated astrocytes. 10 of the 25 proteins showed reduced spectral counts on Tg treatment. These changes were largely reversed by PERK inhibition.

(B) Pie chart showing the percentage of proteins that exhibited an increase, decrease, or no change in spectral counts on Tg treatment.

(C) Bubble plots showing KEGG and GO functional analysis of the proteins that displayed reduced spectral counts on Tg treatment, as determined using DAVID. Terms relating to the extracellular matrix and cell adhesion were significantly enriched upon PERK activation (p < 0.0001). Size of bubble represents protein count. LC/MS was performed on conditioned media from 3 biological replicates.

included BiP and the neurotrophic factor, MANF (Figures 3B and S3; Table S1). 52/127 (41%) proteins showed no change in abundance on Tg treatment (Figure 3B; Table S1). Thus, it is likely that changes to the secretome induced by Tg treatment do not solely reflect the reduction in global protein synthesis rates that accompany PERK activation (Figure 1C) but likely reflect changes in the astrocytic translatome under these conditions. PERK inhibition largely reversed the changes to protein abundance (Figure 3A; Table S1). The UPR-reactivity state resulting from chronic

PERK branch activation therefore alters the secretome of primary astrocytes, to the detriment of synaptic trophism.

Astrocytic PERK-eIF2α Signaling Drives a UPR-Reactivity State *In Vivo* that Is Reversed by Genetic Modulation of the Pathway

Given the effect of PERK signaling on astrocyte reactivity *in vitro* (Figures 1E and S1H), we next examined whether this also occurs *in vivo*. We used the $tg37^{+/-}$ mouse model of prion disease,

which has been extensively characterized with respect to PERKelF2a signaling and its modulation, particularly in neurons (Halliday et al., 2015, 2017; Moreno et al., 2012, 2013). Tg37^{+/-} mice express around ~3-fold wild-type levels of prion protein (PrP) and succumb to RML (Rocky Mountain Laboratory) prion infection 12 weeks post-inoculation (w.p.i.) (Mallucci et al., 2002, 2003, 2007). Rising levels of misfolded PrP result in high PERK-P and eIF2a-P and reduced translation rates in the hippocampus from 9 w.p.i., followed by the onset of neuronal loss at 10 w.p.i., with the emergence of overt clinical signs and widespread neurodegeneration by 12 w.p.i. (Moreno et al., 2012). The mice show prominent astrocytosis from 8 w.p.i., with increased GFAP staining over the course of the disease (Figure S4A), consistent with previous reports (Mallucci et al., 2002, 2003). PERK-P staining was detected in astrocytes and neurons in the CA1 region of prion-infected mice at 10 w.p.i. (Figure S4B).

We examined hippocampal homogenates of prion-diseased mice at 10 w.p.i., when PERK signaling is known to be activated (Moreno et al., 2012) and reactive astrocytosis is established (Figure S4A). We tested for expression of UPR-reactivity markers defined in vitro (Figures 1E and 1F) and found a pattern of mRNA transcript expression very similar to that seen in Tg- and Tmstressed astrocytes (Figures 1E, 1F, and S1H). Thus, mRNA levels of C3, Cxcl10, Lcn2, and Vim rose significantly from 9 w.p.i. (Figures 4A and S5A), in parallel with increased PERKelF2 α signaling (Figure S5C), and remained elevated through to the terminal stages of the disease (Figures 4A and S5A). mRNA levels of Lcn2, a pan-reactive marker, increased more than 250-fold in terminal prion-diseased mice compared to control tg37^{+/-} mice (Figure 4A). Transcript levels of Sox9, an astrocyte-specific nuclear marker, were unchanged through the disease course (Figure S5A), consistent with an altered reactivity state rather than merely reflecting an increase in astrocyte number. RNA scope (Figure 4B) and immunohistochemistry (Figures 4C and 4D) confirmed the astrocytic origins of C3 and Lcn2 transcript and protein, respectively, in prion-diseased mice at 10 w.p.i. The rise in these proteins occurred at 9 w.p.i., in line with increased PERK-eIF2α signaling (Figures S5B-S5D).

In order to modulate PERK-elF2a signaling specifically in astrocytes, we generated lentiviral vectors that overexpress an active fragment of GADD34 (AhuGADD34), the specific inducible phosphatase of eIF2a-P, under the astrocytic promoter GFAP (Figure S6A). LV-GFAP-AhuGADD34-transduced primary astrocytes (Figure S6B) resulted in reduced eIF2a-P levels and increased protein synthesis rates on Tg treatment (Figures S6C and S6D), confirming both functionality of the virus and efficacy of GADD34 activity in cultured astrocytes. In vivo, mice were injected with LV-GFAP-AhuGADD34 at 5 w.p.i. to allow for viral expression as disease progressed. Astrocytic expression of the viral construct was confirmed through detection of lentivirally mediated expression of GFP (linked to AhuGADD34) in hippocampal sections (Figure S6E). Virally expressed ΔhuGADD34 caused reduced eIF2a-P levels in prion-infected mice at 10 w.p.i. (Figures S6F and S6G). Critically, LV-GFAP-AhuGADD34 treatment of prion-infected mice reduced the astrocyte reactivity profile (Figures 5A, S6H, and S6I), consistent with the effects of PERK inhibitor treatment in vitro (Figure 1G). Levels of C3, *Cxcl10, Lcn2*, and *Vim* were reduced by 53%, 63%, 46%, and 35%, respectively, at 10 w.p.i. following LV-GFAP- Δ huGADD34 injection (Figures 5A and S6I). The reduction in *C3* and *Lcn2* transcript levels in astrocytes of GADD34-treated mice was confirmed by RNA scope (Figure 5B). C3 and LCN2 protein levels were also significantly reduced in LV-GFAP- Δ huGADD34-treated mice, consistent with reduced astrocyte activation (Figures 5C and 5D).

Targeting PERK-eIF2 α Signaling in Astrocytes In Vivo Is Profoundly Neuroprotective

In vitro, inhibiting PERK signaling restored the synaptogenic properties of Tg-stressed astrocytes (Figures 2B and 2C). We next asked what were the functional sequelae of modulating PERK signaling in astrocytes in vivo, in the context of over-activation of the pathway during prion neurodegeneration. We first observed that lentivirally mediated astrocyte-specific GADD34 expression in prion-diseased mice resulted in a significant and sustained improvement in burrowing behavior (Figure 6A), a motivational task sensitive to hippocampal (notably CA1) integrity that correlates with early synaptic dysfunction in prion disease (Deacon et al., 2001; Mallucci et al., 2007). Control mice treated with an "empty" virus showed a steady decline in burrowing from 8 w.p.i. In parallel, astrocytic expression of GADD34 reduced spongiform degeneration (Figure 6B, h versus f and g) and largely prevented neurodegeneration in the hippocampus (Figure 6B, a-h). Astrocytic GADD34 expression resulted in marked neuroprotection: LV-GFAP-AhuGADD34treated mice showed 67% more pyramidal neurons in the CA1-CA3 region at 12 w.p.i. than mice treated with LV-GFAPempty or no virus (p = 0.0002; Figures 6B, see h compared to f and g, and 6C). Further, lowering astrocytic PERK signaling through GADD34 overexpression not only reduced the activation state (Figures 5A and S6I) but also significantly decreased astrocyte density (Figures 6B, compare I with j and k, and 6D), with a 35% reduction in astrocyte numbers and markedly less activated morphology in GADD34-treated animals (Figures 5C and 5D, e and f). Finally, lentivirally mediated modulation of astrocytic PERK signaling significantly increased survival in prion-diseased mice to 87 ± 2 days, compared to 82 ± 2 days in mice treated with empty virus (p = 0.0009; Figure 6E). Although this increase may appear modest, this extension of lifespan is comparable to survival data where PERK signaling is similarly modulated in neurons, through lentiviral expression of AhuGADD34 under the neuron-specific CAMKII promoter, and is the result of focal modulation only (Figure S6J; Moreno et al., 2012). As with neuronally targeted PERK modulation, levels of PrP and its misfolded disease-associated isoform, PrPSc, were unaffected by the interventions (Figure S6K). These data strongly implicate the role of astrocytic PERK signaling in neuronal demise during disease, through the loss of critical synaptotrophic support.

DISCUSSION

The processes leading to neurodegeneration involve several cell types other than neurons. The role of microglia in these disorders has been extensively studied, but although astrocyte activation and reactivity are well documented, the mechanisms underlying




Figure 4. UPR-Reactive Astrocytes Upregulate C3 and LCN2 In Vivo

0-

NBH

prion


0.

NBH

prion

(A) qPCR analysis of hippocampal C3 and *Lcn2* mRNA levels across the prion time course. *p < 0.05; **p < 0.01; **p < 0.01; n = 3 mice per time point. (B) RNA scope showing the localization of C3 (magenta) and *Lcn2* (white) to GFAP⁺ astrocytes (green) in the hippocampus of prion-diseased mice at 10 w.p.i. (C and D) Immunostaining of C3 (C) and LCN2 (D) in the hippocampus of prion-diseased mice at 10 w.p.i. Scale bars, 100 μ m.

(E) Prion-diseased mice showed a significant increase in the number of C3⁺/GFAP⁺ and LCN2⁺/GFAP⁺ astrocytes. Bar graphs show mean ± SEM; ***p < 0.001; Student's t test. n = 3 mice.



the astrocytic response to neurodegeneration are still largely unresolved. These cells were the focus of our study.

The pathogenic role of dysregulated PERK-eIF2a-P signaling in neurons has been well characterized across the spectrum of neurodegenerative disorders (Grande et al., 2018; Halliday et al., 2015, 2017; Hoozemans et al., 2005, 2007; Kim et al., 2014; Mercado et al., 2018; Moreno et al., 2012, 2013; Radford et al., 2015; Stutzbach et al., 2013). PERK-P has been detected in astrocytes from human tauopathy diseases (Nijholt et al., 2012), but the pathogenic effect of astrocytic PERK signaling, if any, in these disorders is unknown. Interestingly, the integrated stress response (ISR), mediated by eIF2a-P signaling, is dysregulated in astrocytes and oligodendrocytes in a group of neurodegenerative disorders known as vanishing white matter disease (VWMD). In these diseases, mutations in eIF2B, the key interactor of eIF2a-P, lead to demyelination and white matter loss (Schiffmann et al., 1994; van der Knaap et al., 1997) through altered eIF2a-P signaling in these cells. Here, we show that UPR activation in astrocytes, specifically PERK-eIF2a-P signaling, generates a distinct reactivity state both in vitro and in vivo, associated with loss of astrocytic synaptic trophism and neuroprotective functions. Inhibition of astrocytic PERK signaling reverses this activation state and restores synaptogenic properties to cultured astrocytes (Figures 1I, 2B, and 2C). In vivo, it has the dramatic effect of affording extensive, profound neuroprotection with prevention of behavioral deficits and increased survival in prion-diseased mice (Figures 6A-6E). The extended lifespan (Figure 6E) seen with focal hippocampal modulation of astrocytic PERK signaling is consistent with observed protective effects of lentiviral modulation of GADD34 in neurons and other neuroprotective genetic modifications in priondiseased mice (Moreno et al., 2012; Peretti et al., 2015). This may result from hippocampal neuroprotection modifying behavior in treated mice in a way that allows a modest but significant and consistent increase in survival. Alternatively, it may reflect an extended time course of prion spread when the hippocampus is protected. We found a consistent "UPR-reactive" profile, generated in response to two different ER stressors in vitro, Tg and Tm (Figures 1E and S1H), and to the in vivo stress of disease-associated protein misfolding (Figures 4A and S5), specifically prion protein PrPSc here. In each case, the profile is reversed by direct inhibition of PERK-P by GSK2606414 (Figures 1H and S1H) or downstream of PERK, by inhibition of eIF2a-P signaling using trazodone (Figure S1I) or via lentivirally mediated GADD34 expression in vivo (Figures 5A and S6I). The UPR-reactive profile shares a number of markers with previously described astrocyte reactivity states. A1 reactivity, which is dependent on microglial activation, in particular, has been suggested as representing a "neurotoxic" phenotype of astrocyte activation and has been attributed to contributing to pathogenesis in a number of human neurodegenerative disorders. In fact, although A1 astrocytes are neurotoxic in vitro, the in vivo evidence for the A1 state in disease is confined to the presence of elevated C3 expression in post mortem samples from a variety of neurodegenerative diseases (Liddelow et al., 2017). C3 elevation forms part of the UPR-reactivity profile, probably because this is a common feature of pathological astrocyte activation. However, the role, if any, of C3 in mediating pathogenesis is unclear, and our data support loss of synaptotrophic function of astrocytes over any direct toxic effect as the central pathological process here. Indeed, recent work identified a very similar profile in prion-diseased wild-type mice to the UPR-reactive state we describe, which the authors termed $C3^+/PrP^{Sc}$ -reactive (Hartmann et al., 2019). Interestingly, the C3⁺/PrP^{Sc}-reactivity profile was largely unaffected by eliminating microglia-induced astrocyte activation, through genetic knockout of tumor necrosis factor alpha (TNF- α), interleukin-1 α (IL-1 α), and C1q, confirming its distinction from the A1 state. Indeed, this state may well respond instead to UPR inhibition, given its similarity to the UPR reactivity we describe in a different prion mouse model. Rather than A1, A2, and "pan" reactivity states, we suggest that there are likely to be multiple reactivity profiles for astrocytes in different diseases, driving pathogenesis through loss of neuronal tropism, with or without a degree of direct toxicity.

The importance of the PERK-mediated reactivity state in astrocytes is apparent through its mechanistic effects of altering the secretome, seen in primary astrocytes (Figure 3). UPR-activated astrocytes display a secretome largely devoid of synaptogenic properties. As a result, the astrocytic component of synapse development in cultured hippocampal neurons is absent (Figure 2B). Many extracellular matrix components, notably collagen, fibronectin, and filamin, known for their importance in synapse formation and maintenance (Ferrer-Ferrer and Dityatev, 2018; Hillen et al., 2018), are reduced in UPR-reactive astrocytes (Figure 3A). PERK inhibition restores this property (Figure 3A). Critically, the secretome changes represent potential targets for synaptic rescue and neuroprotection for treatment of neurodegenerative diseases that would avoid systemic, widespread PERK pathway signaling modulation. Indeed, restoring synapse levels through synaptogenic pathways involving the cold-shock proteins RBM3 and RTN3 reverses cognitive deficits and prevents neurodegeneration in mouse models of Alzheimer's and prion disease (Bastide et al., 2017; Peretti et al., 2015) and is a powerful neuroprotective strategy. A more in-depth analysis of the astrocytic secretome-and proteome-may reveal further small molecules or peptides with synaptogenic properties that could be candidates for therapeutic intervention.

In conclusion, dysregulated PERK signaling in astrocytes generates a reactivity state that drives a marked non-cellautonomous mechanism of pathogenesis in prion neurodegeneration, likely to be relevant across the spectrum of these disorders

(A) Prion-inoculated mice were injected with lentivirus at 5 w.p.i., prior to synapse loss. The astrocytic expression of Δ huGADD34 significantly reduced the mRNA levels of the UPR-reactivity markers C3 and Lcn2 at 10 w.p.i., as analyzed by qPCR. **p < 0.01; n = 5 mice per condition.

(B) RNA scope also revealed a reduction in C3 and Lcn2 upon the expression of Δ huGADD34.

Figure 5. Genetic Modulation of Astrocytic PERK-eIF2a Signaling Ameliorates the UPR-Reactivity State In Vivo

⁽C and D) Protein levels of C3 (C) and LCN2 (D) were similarly reduced by astrocytic Δ huGADD34, as determined by immunohistochemistry. Scale bars, 100 μ m. (E) Bar graphs represent quantification of C3⁺ and LCN2⁺ astrocytes treated with Δ huGADD34 or empty virus. Bar graphs show mean ± SEM; ***p < 0.001; Student's t test. n = 3 mice.




Figure 6. Targeting Astrocytic PERK-eIF2a Signaling Is Neuroprotective in Prion-Diseased Mice

(A) Prion-infected mice received hippocampal injections of LV-GFAP-empty or LV-GFAP-ΔhuGADD34 at 5 w.p.i. The overexpression of ΔhuGADD34 prevented the decline in burrowing behavior at 9, 10, and 11 w.p.i.

in which PERK activation occurs. These include the tauopathies, including Alzheimer's disease and many other protein misfolding disorders. Targeting the astrocytic UPR, remarkably, is as protective as targeting the neuronal component. The data reveal new mechanisms by which astrocyte reactivity states contribute to neurodegeneration and provide novel potential synapse-specific targets for therapy.

STAR***METHODS**

Detailed methods are provided in the online version of this paper and include the following:

- KEY RESOURCES TABLE
- LEAD CONTACT AND MATERIALS AVAILABILITY
- EXPERIMENTAL MODEL AND SUBJECT DETAILS
 - Animals
 - Primary astrocyte culture
 - Primary neuron culture
- METHOD DETAILS
 - Prion infection of mice
 - Lentivirus
 - Stereotaxic injection
 - Burrowing assay
 - Immunohistochemistry
 - O Fluorescence in situ RNA hybridization
 - Fluorescence in situ RNA hybridization imaging
 - Western blotting
 - Co-culture with astrocyte conditioned media
 - Synapse quantification
 - LC/MS analysis of astrocyte-conditioned media
 - Drug treatments
 - qPCR
- QUANTIFICATION AND STATISTICAL ANALYSIS
- DATA AND CODE AVAILABILITY

SUPPLEMENTAL INFORMATION

Supplemental Information can be found online at https://doi.org/10.1016/j. neuron.2019.12.014.

ACKNOWLEDGMENTS

We thank Biological Services staff at the University of Cambridge and the University of Leicester. We also thank the Cambridge Centre for Proteomics. G.R.M. is funded by the European Research Council (ERC) (consolidator grant UPR Neuro; no. 647479); the UK Dementia Research Institute, which receives its funding from UK DRI, Ltd. (award UKDRI-2001) funded by the UK Medical Research Council, Alzheimer's Society, and Alzheimer's Research UK; Medical Research Council (MRC MC_U132692719); JPND (MR/R024820/1); CoEN (MR/S00503X/1); and the Wellcome Trust Collaborative Award (201487/Z/16/Z). D.H.R. and R.J.M.F. are funded by the Adelson Medical Research Foundation and UK Multiple Sclerosis Society.

AUTHOR CONTRIBUTIONS

H.L.S. conducted experiments and wrote the paper; O.J.F., A.J.B., I.H., S.H., T.S., D.T.H., N.C.V., D.P.S., J.H., and L.d.W. conducted experiments; and D.H.R. and R.J.M.F. contributed to study design. G.R.M. designed the study, supervised the work, and wrote the paper.

DECLARATION OF INTERESTS

The authors declare no competing interests. O.J.F. is now an employee of AstraZeneca.

Received: July 26, 2019 Revised: November 6, 2019 Accepted: December 9, 2019 Published: January 7, 2020

REFERENCES

Allen, N.J., Bennett, M.L., Foo, L.C., Wang, G.X., Chakraborty, C., Smith, S.J., and Barres, B.A. (2012). Astrocyte glypicans 4 and 6 promote formation of excitatory synapses via GluA1 AMPA receptors. Nature *486*, 410–414.

Axten, J.M., Medina, J.R., Feng, Y., Shu, A., Romeril, S.P., Grant, S.W., Li, W.H., Heerding, D.A., Minthorn, E., Mencken, T., et al. (2012). Discovery of 7-methyl-5-(1-{[3-(trifluoromethyl)phenyl]acetyl}-2,3-dihydro-1H-indol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (GSK2606414), a potent and selective first-in-class inhibitor of protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK). J. Med. Chem. 55, 7193–7207.

Bastide, A., Peretti, D., Knight, J.R., Grosso, S., Spriggs, R.V., Pichon, X., Sbarrato, T., Roobol, A., Roobol, J., Vito, D., et al. (2017). RTN3 is a novel cold-induced protein and mediates neuroprotective effects of RBM3. Curr. Biol. *27*, 638–650.

Celardo, I., Costa, A.C., Lehmann, S., Jones, C., Wood, N., Mencacci, N.E., Mallucci, G.R., Loh, S.H., and Martins, L.M. (2016). Mitofusin-mediated ER stress triggers neurodegeneration in pink1/parkin models of Parkinson's disease. Cell Death Dis. 7, e2271.

Christopherson, K.S., Ullian, E.M., Stokes, C.C., Mullowney, C.E., Hell, J.W., Agah, A., Lawler, J., Mosher, D.F., Bornstein, P., and Barres, B.A. (2005). Thrombospondins are astrocyte-secreted proteins that promote CNS synaptogenesis. Cell *120*, 421–433.

Chung, W.S., Clarke, L.E., Wang, G.X., Stafford, B.K., Sher, A., Chakraborty, C., Joung, J., Foo, L.C., Thompson, A., Chen, C., et al. (2013). Astrocytes mediate synapse elimination through MEGF10 and MERTK pathways. Nature *504*, 394–400.

Costa-Mattioli, M., Gobert, D., Stern, E., Gamache, K., Colina, R., Cuello, C., Sossin, W., Kaufman, R., Pelletier, J., Rosenblum, K., et al. (2007). elF2alpha phosphorylation bidirectionally regulates the switch from short- to long-term synaptic plasticity and memory. Cell *129*, 195–206.

Deacon, R.M., Raley, J.M., Perry, V.H., and Rawlins, J.N. (2001). Burrowing into prion disease. Neuroreport *12*, 2053–2057.

Ferrer-Ferrer, M., and Dityatev, A. (2018). Shaping synapses by the neural extracellular matrix. Front. Neuroanat. *12*, 40.

Grande, V., Ornaghi, F., Comerio, L., Restelli, E., Masone, A., Corbelli, A., Tolomeo, D., Capone, V., Axten, J.M., Laping, N.J., et al. (2018). PERK inhibition delays neurodegeneration and improves motor function in a mouse model of Marinesco-Sjögren syndrome. Hum. Mol. Genet. *27*, 2477–2489.

Guthrie, L.N., Abiraman, K., Plyler, E.S., Sprenkle, N.T., Gibson, S.A., McFarland, B.C., Rajbhandari, R., Rowse, A.L., Benveniste, E.N., and

(B) Representative images of hematoxylin-and-eosin-stained hippocampus from normal brain homogenate (NBH) and prion-inoculated mice injected with LV-GFAP-empty or LV-GFAP-ΔhuGADD34. Scale bars, (a–d) 200 μm; (e–j) 50 μm.

- (C) Astrocytic expression of Δ huGADD34 resulted in profound neuroprotection.
- (D) The levels of GFAP were also reduced.

(E) Targeting astrocytic PERK-elF2α significantly prolonged survival. LV-GFAP-empty = 6 mice; LV-GFAP-ΔhuGADD34 = 11 mice. ***p < 0.001; Mantel-Cox test.

Meares, G.P. (2016). Attenuation of PKR-like ER kinase (PERK) signaling selectively controls endoplasmic reticulum stress-induced inflammation without compromising immunological responses. J. Biol. Chem. *291*, 15830–15840.

Halliday, M., Radford, H., Sekine, Y., Moreno, J., Verity, N., le Quesne, J., Ortori, C.A., Barrett, D.A., Fromont, C., Fischer, P.M., et al. (2015). Partial restoration of protein synthesis rates by the small molecule ISRIB prevents neurodegeneration without pancreatic toxicity. Cell Death Dis. *6*, e1672.

Halliday, M., Radford, H., Zents, K.A.M., Molloy, C., Moreno, J.A., Verity, N.C., Smith, E., Ortori, C.A., Barrett, D.A., Bushell, M., and Mallucci, G.R. (2017). Repurposed drugs targeting elF2&a;-P-mediated translational repression prevent neurodegeneration in mice. Brain *140*, 1768–1783.

Hartmann, K., Sepulveda-Falla, D., Rose, I.V.L., Madore, C., Muth, C., Matschke, J., Butovsky, O., Liddelow, S., Glatzel, M., and Krasemann, S. (2019). Complement 3⁺-astrocytes are highly abundant in prion diseases, but their abolishment led to an accelerated disease course and early dysregulation of microglia. Acta Neuropathol. Commun. 7, 83.

Hillen, A.E.J., Burbach, J.P.H., and Hol, E.M. (2018). Cell adhesion and matricellular support by astrocytes of the tripartite synapse. Prog. Neurobiol. *165-167*, 66–86.

Hoozemans, J.J., Veerhuis, R., Van Haastert, E.S., Rozemuller, J.M., Baas, F., Eikelenboom, P., and Scheper, W. (2005). The unfolded protein response is activated in Alzheimer's disease. Acta Neuropathol. *110*, 165–172.

Hoozemans, J.J., van Haastert, E.S., Eikelenboom, P., de Vos, R.A., Rozemuller, J.M., and Scheper, W. (2007). Activation of the unfolded protein response in Parkinson's disease. Biochem. Biophys. Res. Commun. *354*, 707–711.

Hoozemans, J.J., van Haastert, E.S., Nijholt, D.A., Rozemuller, A.J., Eikelenboom, P., and Scheper, W. (2009). The unfolded protein response is activated in pretangle neurons in Alzheimer's disease hippocampus. Am. J. Pathol. *174*, 1241–1251.

Kim, H.J., Raphael, A.R., LaDow, E.S., McGurk, L., Weber, R.A., Trojanowski, J.Q., Lee, V.M., Finkbeiner, S., Gitler, A.D., and Bonini, N.M. (2014). Therapeutic modulation of eIF2 α phosphorylation rescues TDP-43 toxicity in amyotrophic lateral sclerosis disease models. Nat. Genet. *46*, 152–160.

Kucukdereli, H., Allen, N.J., Lee, A.T., Feng, A., Ozlu, M.I., Conatser, L.M., Chakraborty, C., Workman, G., Weaver, M., Sage, E.H., et al. (2011). Control of excitatory CNS synaptogenesis by astrocyte-secreted proteins Hevin and SPARC. Proc. Natl. Acad. Sci. USA *108*, E440–E449.

Liddelow, S.A., Guttenplan, K.A., Clarke, L.E., Bennett, F.C., Bohlen, C.J., Schirmer, L., Bennett, M.L., Münch, A.E., Chung, W.S., Peterson, T.C., et al. (2017). Neurotoxic reactive astrocytes are induced by activated microglia. Nature *541*, 481–487.

Ma, T., Trinh, M.A., Wexler, A.J., Bourbon, C., Gatti, E., Pierre, P., Cavener, D.R., and Klann, E. (2013). Suppression of eIF2 α kinases alleviates Alzheimer's disease-related plasticity and memory deficits. Nat. Neurosci. *16*, 1299–1305.

Mahameed, M., Wilhelm, T., Darawshi, O., Obiedat, A., Tommy, W.S., Chintha, C., Schubert, T., Samali, A., Chevet, E., Eriksson, L.A., et al. (2019). The unfolded protein response modulators GSK2606414 and KIRA6 are potent KIT inhibitors. Cell Death Dis. *10*, 300.

Mallucci, G.R., Ratté, S., Asante, E.A., Linehan, J., Gowland, I., Jefferys, J.G., and Collinge, J. (2002). Post-natal knockout of prion protein alters hippocampal CA1 properties, but does not result in neurodegeneration. EMBO J. *21*, 202–210.

Mallucci, G., Dickinson, A., Linehan, J., Klöhn, P.C., Brandner, S., and Collinge, J. (2003). Depleting neuronal PrP in prion infection prevents disease and reverses spongiosis. Science *302*, 871–874.

Mallucci, G.R., White, M.D., Farmer, M., Dickinson, A., Khatun, H., Powell, A.D., Brandner, S., Jefferys, J.G., and Collinge, J. (2007). Targeting cellular

prion protein reverses early cognitive deficits and neurophysiological dysfunction in prion-infected mice. Neuron 53, 325–335.

Mercado, G., Castillo, V., Soto, P., López, N., Axten, J.M., Sardi, S.P., Hoozemans, J.J.M., and Hetz, C. (2018). Targeting PERK signaling with the small molecule GSK2606414 prevents neurodegeneration in a model of Parkinson's disease. Neurobiol. Dis. *112*, 136–148.

Moreno, J.A., Radford, H., Peretti, D., Steinert, J.R., Verity, N., Martin, M.G., Halliday, M., Morgan, J., Dinsdale, D., Ortori, C.A., et al. (2012). Sustained translational repression by elF2 α -P mediates prion neurodegeneration. Nature *485*, 507–511.

Moreno, J.A., Halliday, M., Molloy, C., Radford, H., Verity, N., Axten, J.M., Ortori, C.A., Willis, A.E., Fischer, P.M., Barrett, D.A., and Mallucci, G.R. (2013). Oral treatment targeting the unfolded protein response prevents neuro-degeneration and clinical disease in prion-infected mice. Sci. Transl. Med. *5*, 206ra138.

Nijholt, D.A., van Haastert, E.S., Rozemuller, A.J., Scheper, W., and Hoozemans, J.J. (2012). The unfolded protein response is associated with early tau pathology in the hippocampus of tauopathies. J. Pathol. *226*, 693–702.

Peretti, D., Bastide, A., Radford, H., Verity, N., Molloy, C., Martin, M.G., Moreno, J.A., Steinert, J.R., Smith, T., Dinsdale, D., et al. (2015). RBM3 mediates structural plasticity and protective effects of cooling in neurodegeneration. Nature *518*, 236–239.

Radford, H., Moreno, J.A., Verity, N., Halliday, M., and Mallucci, G.R. (2015). PERK inhibition prevents tau-mediated neurodegeneration in a mouse model of frontotemporal dementia. Acta Neuropathol. *130*, 633–642.

Rojas-Rivera, D., Delvaeye, T., Roelandt, R., Nerinckx, W., Augustyns, K., Vandenabeele, P., and Bertrand, M.J.M. (2017). When PERK inhibitors turn out to be new potent RIPK1 inhibitors: critical issues on the specificity and use of GSK2606414 and GSK2656157. Cell Death Differ. 24, 1100–1110.

Ron, D., and Walter, P. (2007). Signal integration in the endoplasmic reticulum unfolded protein response. Nat. Rev. Mol. Cell Biol. 8, 519–529.

Schiffmann, R., Moller, J.R., Trapp, B.D., Shih, H.H., Farrer, R.G., Katz, D.A., Alger, J.R., Parker, C.C., Hauer, P.E., Kaneski, C.R., et al. (1994). Childhood ataxia with diffuse central nervous system hypomyelination. Ann. Neurol. *35*, 331–340.

Sidrauski, C., Acosta-Alvear, D., Khoutorsky, A., Vedantham, P., Hearn, B.R., Li, H., Gamache, K., Gallagher, C.M., Ang, K.K., Wilson, C., et al. (2013). Pharmacological brake-release of mRNA translation enhances cognitive memory. eLife *2*, e00498.

Smith, H.L., and Mallucci, G.R. (2016). The unfolded protein response: mechanisms and therapy of neurodegeneration. Brain *139*, 2113–2121.

Sprenkle, N.T., Lahiri, A., Simpkins, J.W., and Meares, G.P. (2019). Endoplasmic reticulum stress is transmissible in vitro between cells of the central nervous system. J. Neurochem. *148*, 516–530.

Stutzbach, L.D., Xie, S.X., Naj, A.C., Albin, R., Gilman, S., Lee, V.M., Trojanowski, J.Q., Devlin, B., and Schellenberg, G.D.; PSP Genetics Study Group (2013). The unfolded protein response is activated in disease-affected brain regions in progressive supranuclear palsy and Alzheimer's disease. Acta Neuropathol. Commun. *1*, 31.

Ullian, E.M., Sapperstein, S.K., Christopherson, K.S., and Barres, B.A. (2001). Control of synapse number by glia. Science *291*, 657–661.

van der Knaap, M.S., Barth, P.G., Gabreëls, F.J., Franzoni, E., Begeer, J.H., Stroink, H., Rotteveel, J.J., and Valk, J. (1997). A new leukoencephalopathy with vanishing white matter. Neurology *48*, 845–855.

Zamanian, J.L., Xu, L., Foo, L.C., Nouri, N., Zhou, L., Giffard, R.G., and Barres, B.A. (2012). Genomic analysis of reactive astrogliosis. J. Neurosci. *32*, 6391–6410.

KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER						
Antibodies								
Rabbit anti-PERK-P (T980)	Cell Signaling Technology	Cat# 3179; RRID: AB_2095853						
Rabbit anti-PERK	Cell Signaling Technology	Cat# 3192; RRID: AB_2095847						
Rabbit anti-elF2α-P (S51)	Cell Signaling Technology	Cat# 3597; RRID: AB_390740						
Mouse anti-elF2a	Cell Signaling Technology	Cat# 2103; RRID: AB_836874						
Rabbit anti-ATF4	Santa Cruz Biotechnology	Cat# sc-390063; RRID: AB_2810998						
Rabbit anti-GADD34	Proteintech	Cat# 10449-1-AP; RRID: AB_2168724						
Mouse anti-puromycin	Millipore	Cat# MABE343; RRID: AB_2566826						
Rabbit anti-β-actin	Abcam	Cat# ab8227; RRID: AB_2305186						
Rabbit anti-synaptophysin	Synaptic Systems	Cat# 101 002; RRID: AB_887905						
Mouse anti-PSD-95	Millipore	Cat# MABN68; RRID: AB_10807979						
Goat anti-C3	R&D Systems	Cat# AF2655; RRID: AB_2066622						
Goat anti-LCN2	R&D Systems	Cat# AF1857; RRID: AB_355022						
Chicken anti-GFAP	Abcam	Cat# ab4674; RRID: AB_304558						
Mouse anti-NeuN	Abcam	Cat# ab104224; RRID: AB_10711040						
Rabbit anti-Iba1	Abcam	Cat# ab178846; RRID: AB_2636859						
Rabbit anti-PrP	D-GEN	Cat# ICSM35						
Bacterial and Virus Strains								
_V-CAMKII-GFP	This paper	N/A						
_V-CAMKII-∆huGADD34	This paper	N/A						
_V-GFAP-GFP	This paper	N/A						
_V-GFAP-∆huGADD34	This paper	N/A						
Biological Samples								
Mouse brain tissue	Strains listed in this table	N/A						
Chemicals, Peptides, and Recombinant Proteins								
Thapsigargin	Thermo Fisher Scientific	Cat# T7459; CAS: 67526-95-8						
Tunicamycin	Sigma-Aldrich	Cat# T7765; CAS: 11089-65-9						
GSK2606414	GlaxoSmithKline	N/A						
Trazodone	Sigma-Aldrich	Cat# T6154; CAS: 25332-39-2						
ΓΝFα	Cell Signaling	Cat# 8902						
IL-1α	Sigma-Aldrich	Cat# I3901						
C1q	Biorad	Cat# 2221-5504						
Critical Commercial Assays								
Ggta1 Taqman assay	Thermo Fisher Scientific	Cat# Mm01333302_m1						
H2-T23 Taqman assay	Thermo Fisher Scientific	Cat# Mm00439246_g1						
Serping1 Taqman assay	Thermo Fisher Scientific	Cat# Mm00437835_m1						
Cd109 Taqman assay	Thermo Fisher Scientific	Cat# Mm00462151_m1						
Emp1 Taqman assay	Thermo Fisher Scientific	 Cat# Mm00515678_m1						
S100a10 Taqman assay	Thermo Fisher Scientific	Cat# Mm00501458_g1						
Experimental Models: Cell Lines								
Mouse: C57BL/6N primary cortical astrocytes	Generated in house	N/A						
Mouse: C56BL/6N primary hippocampal neurons	Generated in house	N/A						

(Continued on next page)

Continued		
REAGENT or RESOURCE	SOURCE	IDENTIFIER
Experimental Models: Organisms/Strains		
tg37 ^{+/-} mice	Imperial College, London	Mallucci et al., 2002
C57BL/6N mice	Charles River	Strain code: 027
Oligonucleotides		
Oligonucleotides for qPCR (see Table S2 for sequences)	Sigma Aldrich	N/A
esiRNA universal negative control	Sigma-Aldrich	Cat# SIC001
esiRNA targeting mouse Eif2ak3	Sigma-Aldrich	Cat# EMU014751
Recombinant DNA		
LV-CAMKII-GFP	Vigene Biosciences	Custom made
LV-CAMKII-∆huGADD34	Vigene Biosciences	Custom made
LV-GFAP-GFP	Vigene Biosciences	Custom made
LV-GFAP-∆huGADD34	Vigene Biosciences	Custom made
Software and Algorithms		
Prism	GraphPad	https://www.graphpad.com
ImageJ	National Institute of Health	https://imagej.nih.gov/ij/docs/guide/ user-guide.pdf
Fiji	Fiji	https://fiji.sc
Photoshop CS6	Adobe Inc.	https://www.adobe.com/products/ photoshop.html
Illustrator CS6	Adobe Inc.	https://www.adobe.com/products/ illustrator.html

LEAD CONTACT AND MATERIALS AVAILABILITY

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Giovanna Mallucci (gm522@cam.ac.uk). All unique reagents generated in this study are available from the Lead Contact with a completed Materials Transfer Agreement.

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Animals

Tg37^{+/-} mice, on a FVB background, were housed in a temperature-controlled room and were maintained on a 12:12 light dark cycle, with access to food and water *ad libitum*. Both males and females were used in this study. Mice were inoculated with 1% brain homogenate of Chandler/Rocky Mountain Laboratory (RML) prions or normal brain homogenate (NBH) at 3-4 weeks of age, as previously described (Moreno et al., 2012). Prion-inoculated mice were monitored daily and were culled upon the appearance of confirmatory prion signs, which occur around 12 weeks post inoculation. Mice were randomly assigned to experimental groups. All animal work conformed to UK Home Office regulations and institutional and ARRIVE guidelines.

Primary astrocyte culture

Primary astrocytes were isolated from the cortices of both male and female P1 C57BL6/N pups. Briefly, cortical tissue was extracted into Hibernate A media (GIBCO); meninges were removed and tissue was minced using a scalpel blade. The minced tissue was then incubated at 37° C for 5 minutes in fresh Hibernate A media supplemented with 1 mg/mL DNase (Sigma) and 0.25% Trypsin (GIBCO). The suspension was triturated then returned to 37° C for 5 minutes. Trituration was repeated and the suspension was incubated for a further 5 minutes. 10 mL of glial media (MEM, 10% horse serum, 0.6% D-glucose and 1% Penicillin/Streptomycin) was added and trituration was performed. The suspension was strained then centrifuged at 200 x g for 5 minutes. The cell pellet was re-suspended in glial media and seeded into T75 flasks (Corning). Cultures were maintained at 37° C, 5% CO₂ in glial media containing 1% horse serum. Upon reaching confluency, astrocytes were seeded into 6 well plates (Greiner) at a density of 100,000 cells per well.

Primary neuron culture

Primary neurons were isolated from the hippocampi of both male and female P1 C57BL6/N pups. Briefly, hippocampi were extracted into Hibernate A media (GIBCO) and incubated at 37°C with papain solution for 20 minutes. Papain solution was removed and trypsin

inhibitor was added for 5 minutes. Hippocampi were then washed 3 times in pre-warmed plating media (Neurobasal A, B27 supplement, Glutamax, Horse serum, 1M HEPES pH 7.5) before being triturated 8-10 times. The suspension was strained and 300,000 cells were seeded onto glass coverslips coated with poly-L-lysine. Media was changed to neuron media (Neurobasal A, B27 supplement, Glutamax, Penicillin/Streptomycin) 4 hours post seeding. Primary neurons were maintained at 37°C, 5% CO₂. A third of the media was changed for fresh media every 3-4 days.

METHOD DETAILS

Prion infection of mice

All animal work conformed to UK Home Office regulations and institutional and ARRIVE guidelines. Tg37^{+/-} mice (males and females), aged 3-4 weeks, were inoculated with 1% brain homogenate of Chandler/Rocky Mountain Laboratory (RML) prions or normal brain homogenate (NBH), as previously described (Moreno et al., 2012). Animals were culled when they developed clinical signs of prion disease, which occurs around 12 weeks post inoculation.

Lentivirus

Lentiviral plasmids were generated by Vigene Biosciences. The catalytically active fragment of human GADD34 was N-terminally FLAG tagged and placed downstream of either a CAMKII or GFAP promoter. A T2a sequence linked Δ huGADD34 to GFP. Plasmids were packaged by Vigene Biosciences or in house, through the calcium-phosphate transfection of HEK293T cells. Final titers were 1x10⁸ TU/mL.

Stereotaxic injection

Prion-infected mice were stereotaxically injected with lentivirus at 5 w.p.i. under general anesthesia. 5 μ L of virus was injected using a Hamilton syringe at the following 4 sites relative to bregma: (-2.0 mm, +2.0 mm, -2.2 mm), (-2.7 mm, +2.0 mm, -2.2 mm), (-2.0 mm, -2.2 mm) and (-2.7 mm, -2.0 mm, -2.2 mm).

Burrowing assay

Burrowing was performed as previously described (Moreno et al., 2013). Briefly, female mice were individually placed in large plastic cages containing a Perspex tube filled with food pellets. The weight of pellets remaining in the tube after 2 hours was measured and the percentage burrowed was calculated.

Immunohistochemistry

For neuronal counts, paraffin-embedded brains were sectioned at 4 µm and were stained with hematoxylin and eosin (H&E) or NeuN (Millipore) as previously described (Moreno et al., 2013). CA1 pyramidal neuronal counts were determined with three serial sections from three separate mice. For immunofluorescence, sections were baked at 55°C for 2 hours before being submerged in 10x Heat Mediated Antigen Retrieval Solution pH 6.0 (Abcam) and left overnight at 60°C. Slides were then washed and blocked for 1 hour in 10% goat serum, 0.1% Triton X-100, 0.3M glycine. Primary antibodies were incubated overnight at 4°C. Following washes, Alexa Fluors (Invitrogen) were applied for 1 hour at room temperature. Slides were mounted with ProLong Diamond Antifade with DAPI (Invitrogen). Images were captured on a Leica 4000B microscope.

Fluorescence in situ RNA hybridization

Fluorescence in situ RNA hybridization (FISH) on brain cryosections was automated on BOND RX robotic stainer (Leica). After manual post-fixation, epitope retrieval and dehydration, cryosections were processed for 3-plex FISH using the RNAScope LS Multiplex Assay (ACD) in combination with immunohistochemistry. Tissues were probed against mRNA transcripts C3 (1:1), Lcn2 (1:50) and GFAP protein (1:2000). The assay was performed according to the manufacturer's instructions. In brief, samples were permeabilised with heat and protease treatment to improve probe penetration and hybridization. For heat treatment, samples were incubated in BOND ER2 buffer (pH 9.0, Leica) at 95°C for 2 minutes. For protease treatment, samples were incubated in ACD protease reagent at 42°C for 10 minutes. Prior to probe hybridization, samples were incubated in hydrogen peroxide for 10 minutes to inactivate endogenous peroxidases and ACD protease. Samples were then incubated in target z-probe mixtures for 2 hours at 42°C. Each slide was flushed three times in order to obtain optimal hybridization to transcripts. Following hybridization, branched DNA amplification trees were built through sequential incubations in AMP1, AMP2 and AMP3 reagents for 15-30 minutes, each at 42°C, with LS Rinse buffer (Leica) high stringency washes in-between incubation steps. After amplification, probe channels were detected sequentially by HRP-TSA labeling. Here, samples were incubated in channel-specific HRP reagents for 15 minutes at 42°C, TSA fluorophores for 30 minutes and HRP blocking reagent for 15 minutes at 42°C. Probes were labeled using Atto 425-Streptavidin (Sigma, 40709, 1:400). Directly following FISH assay, localization of GFAP protein was performed by BOND RX assisted IHC. Samples were incubated with anti-GFAP antibody in blocking solution for 1 hour (Abcam). To develop the antibody signal, samples were incubated in donkey anti-goat HRP (Thermo Fisher Scientific) for 1 hour, TSA biotin (PE) for 10 minutes and streptavidin-conjugated Alexa 700-streptavidin (Sigma) for 30 minutes.

Fluorescence in situ RNA hybridization - imaging

High-resolution FISH images of tissue sections were acquired on a spinning disk Operetta CLS (Perkin Elmer) in confocal mode using a sCMOS camera and a 40X NA 1.1 automated-water dispensing objective. The machine was equipped with custom-made narrow band filters to allow hex-plex imaging. The field-of-view was $320 \times 320 \mu m$ and voxel size $0.3 \times 0.3 \times 1 \mu m$. Each field was imaged as a z stack consisting of 20 to 30 planes with a 1 μm step size. Z-heights of tissue sections were manually determined by imaging DAPI on sample fields prior to tissue-wide scans. Each z-plane was imaged across 6 channels with exposure times between 60 and 120 ms at 80% LED power. The background correction was applied uniformly across samples, according to control tissue probed with negative probes and by omitting primary antibody.

Western blotting

Protein samples were isolated from hippocampi or astrocyte cell pellets using RIPA lysis buffer (150 μ L NaCl, 50 mM Tris, 0.5% sodium deoxycholate, 0.1% SDS and 1% Triton X-100) supplemented with Phos-STOP and protease inhibitors (Roche). 15 μ g of protein was resolved by SDS-PAGE then transferred onto nitrocellulose or PVDF membranes. Membranes were incubated overnight with primary antibodies. Horseradish peroxidase secondary antibodies were applied for 1 hour at room temperature at a 1:10,000 dilution (Goat anti-mouse, goat anti-rabbit (BioRad), donkey anti-goat (Promega)). Secondary antibodies were detected with the enhanced chemiluminescence system (ECL, GE Healthcare). β -actin or GAPDH was used as a loading control and quantitative analysis was performed with ImageJ.

Co-culture with astrocyte conditioned media

Astrocytes were seeded into 6 well plates at a density of 100,000 cells per well. At 90% confluency, media was removed and cells were washed 3 times with Neurobasal A (GIBCO). Astrocytes were then cultured in neuron media for 24 hours. Vehicle or drug treatments were added for 24 hours. Media was then removed, astrocytes were washed 3 times with Neurobasal A and fresh neuron media was added. Following 24 hours, astrocyte-conditioned neuron media was collected and centrifuged at 200 x g to remove dead cells. Astrocyte-conditioned media was transferred to hippocampal neurons at 18 DIV.

Synapse quantification

Neurons were fixed in 4% paraformaldehyde, 4% sucrose for 20 minutes. Coverslips were washed with PBS then incubated with 0.1% Triton X-100 for 5 minutes, followed by 50 mM NH₄Cl for 20 minutes. Neurons were then blocked in 10% goat serum for 1 hour at room temperature. Synaptophysin (Synaptic Systems) and PSD-95 (Millipore) antibodies were diluted in blocking solution and were incubated overnight at 4°C. Following washes in PBS, neurons were incubated for 1 hour at room temperature with anti-mouse Alexa Fluor 488 and anti-rabbit Alexa Fluor 568 (Thermo). Coverslips were stained with DAPI prior to mounting. Images were captured using a Leica confocal microscope at 63x magnification. The number of co-localized puncta was quantified using the JACoP plugin in ImageJ. Synapse numbers from 10 neurons were counted per condition per biological replicate.

LC/MS analysis of astrocyte-conditioned media

Astrocytes were seeded into 6-well plates at a density of 100,000 cells. At 90% confluency, cells were washed 3 times with Neurobasal A (GIBCO), then cultured overnight in serum-free media (Neurobasal A, Glutamax and Penicillin/Streptomycin). Astrocytes were treated for 24 hours with vehicle, thapsigargin or both thapsigargin and GSK2606414. Media was collected and centrifuged for 5 minutes at 4,000 x g to remove any dead cells. Proteins were precipitated using trichloroacetic acid. Precipitates were washed with acetone, resuspended in SDS-PAGE buffer and separated on a 4%–12% gel. The precipitation procedure was also performed on serum-free media alone, as an additional control. Proteins were analyzed by LC/MS. A protein was identified if it received \geq 99% confidence with \geq 3 unique peptides at 95% confidence in the vehicle- or thapsigargin-treated condition.

Drug treatments

Astrocytes were treated with 300 nM thapsigargin (Thermo) or 3 μ g/mL tunicamycin (Sigma) for the indicated time periods. GSK2606414 and trazodone were added at the same time as the ER stressor, at concentrations of 5 μ M and 20 μ M, respectively. The 'A1-cocktail' was composed of TNF α (30 ng/mL), C1q (400 ng/mL) and IL-1 α (3 ng/mL).

qPCR

Total RNA was isolated with the RNeasy micro kit (QIAGEN), according to manufacturer's instructions. mRNA was reverse transcribed using the Superscript IV First-Strand Synthesis system (Thermo) and qPCR was performed with Power SYBR Green master mix (Applied Biosystems). Primers were designed using NCBI primer Basic Local Alignment Search Tool (BLAST) software. Primer sequences are listed in Table S2. Primer pairs spanned exon-exon junctions, to avoid amplification of genomic DNA. 300 nM forward primer, 300 nM reverse primer and 1 μ L cDNA was used per reaction. qPCR was performed using the QuantStudio 7 Real-Time System (Applied Biosystems) with the following thermal cycling conditions: 95°C for 10 minutes, followed by 40 cycles of 95°C for 15 s, 60°C for 1 minute. All primers pairs amplified a single product, as determined using a melt curve. Data was processed using QuantStudio 6 and 7 Flex software and is expressed as 2^{-ΔCT}.

QUANTIFICATION AND STATISTICAL ANALYSIS

Statistical details for each experiment, including *n* numbers and the statistical test performed, can be found in the corresponding figure legend. Data are presented as mean \pm standard error of the mean (SEM). Statistical analysis was performed using Prism V6 software. Student's t test was used for datasets with a normal distribution and a single intervention. One-way ANOVA was performed with Tukey's post hoc test for multiple comparisons. Survival data was analyzed using Mantel-Cox. p < 0.05 was considered statistically significant.

DATA AND CODE AVAILABILITY

The published article includes all datasets generated during this study.

Neuron, Volume 105

Supplemental Information

Astrocyte Unfolded Protein Response Induces

a Specific Reactivity State that Causes

Non-Cell-Autonomous Neuronal Degeneration

Heather L. Smith, Oliver J. Freeman, Adrian J. Butcher, Staffan Holmqvist, Ibrahim Humoud, Tobias Schätzl, Daniel T. Hughes, Nicholas C. Verity, Dean P. Swinden, Joseph Hayes, Lis de Weerd, David H. Rowitch, Robin J.M. Franklin, and Giovanna R. Mallucci






Figure S1 (related to Figure 1). Thapsigargin and tunicamycin induce a reactive phenotype in primary cultured astrocytes. (A) Purity of primary astrocyte cultures. Staining for the astrocyte-specific marker, GFAP and the microglial-specific marker, Iba1, revealed a purity of more than 80%. (B) Western blot analysis of PERK branch markers in primary astrocytes treated with 3 μ g/mL tunicamycin (Tm) for 2, 6 or 24 hours. Quantification of western blots shown in (C). (D) Protein synthesis rates were reduced following 2 hours of Tm treated, measured using puromycin incorporation into nascent proteins. Quantification of western blot shown in (E). (F) Positive control for the detection of a 'reactive' astrocyte profile by qPCR. Primary astrocytes were treated with the 'A1-cocktail' (TNF α , C1q and IL-1 α) for 24 hours. 'Pan'- and 'A1'-reactive markers were significantly upregulated, whilst 'A2'-reactive markers were downregulated. (G) Reactivity profile of primary

astrocytes following 2 or 6 hours of Tg treatment. An altered reactivity state was observed from 6 hours onwards. (H) qPCR analysis of reactivity markers following 24 hours of Tm treatment. The PERK inhibitor, GSK2606414, largely restores the reactivity signature observed on ER stress. (I) Trazodone (20 μ M) partially restores the reactivity profile of Tg-stressed astrocytes, reducing the upregulation of *Cxcl10, Lcn2, Vim* and C3. All bar graphs show mean ± SEM. **p* <0.05, ***p* <0.01, ****p* <0.001, one-way ANOVA. *n* = 3 biological replicates.

Figure S2 (related to Figure 1)




Figure S2 (related to Figure 1). Genetic modulation of PERK-elF2 α signalling reduces astrocyte reactivity on Tg treatment. (A) The knockdown of PERK using siRNA significantly lowered the levels of elF2 α -P and GADD34 on Tg treatment. Quantification of western blots shown in (B). (C) PERK knockdown significantly blunts the upregulation of *Cxcl10, C3, Lcn2* and *Vim* on Tg treatment. All bar graphs show mean \pm SEM. *p <0.05, **p <0.01, ***p <0.001, one-way ANOVA. n = 3 biological replicates.

Figure S3 (related to Figure 3)




Figure S3 (related to Figure 3). UPR-reactive astrocytes have an altered secretome. Bubble plots showing KEGG and GO functional analysis of proteins that displayed increased spectral counts on Tg treatment, as determined using DAVID. 'Protein processing in the endoplasmic reticulum' and 'protein disulphide isomerase activity' were the most significantly enriched pathways, as determined by KEGG and GO Molecular Function, respectively (*p*-value <0.0001). Size of bubble represents protein count. LC/MS was performed on conditioned media from 3 biological replicates.

Figure S4 (related to Figure 4)




Figure S4 (related to Figure 4). Prion-diseased mice show prominent astrocytosis from 8 w.p.i. (A) Representative images of GFAP stained hippocampal sections from NBH and prion-diseased mice illustrating increased astrocytosis across the disease time course. Scale bar, 50 μ m (B) Hippocampal sections from prion-diseased mice at 10 w.p.i. showing PERK-P staining (magenta) in both the neuronal cell bodies (NeuN, blue) and astrocytes (GFAP, green). Scale bar, 10 μ m.

Figure S5 (related to Figure 4)




Figure S5 (related to Figure 4). Astrocyte reactivity markers are elevated in prion-diseased mice. (A) qPCR analysis of reactivity markers in hippocampal lysates from NBH and prion-inoculated mice. 9 out of the 11 markers show increased levels from 9 and 10 w.p.i. The upregulation of *Cxcl10* occurs slightly earlier, at 8 w.p.i. The mRNA levels of *Sox9*, a nuclear-specific marker that accounts for astrocyte number, remains unchanged through the course of the disease. Bar graphs show mean \pm SEM. **p* <0.05, ***p* <0.01, ****p* <0.001, one-way ANOVA. *n* = 3 mice per time point. (B) Western blot analysis of C3 and LCN2 protein levels in hippocampal homogenates from NBH and prion-

diseased mice at 8, 9 and 10 w.p.i. (**C**) The increase in C3 and LCN2 protein at 9 w.p.i. correlates with increased PERK-eIF2 α signalling. Quantification of western blots shown in (**D**). Bar graphs show mean \pm SEM. **p* <0.05, ***p* <0.01, one-way ANOVA. *n* = 3-5 mice per time point.

Figure S6 (related to Figures 5 and 6)




Figure S6 (related to Figures 5 and 6). LV-GFAP- Δ huGADD34 reduces eIF2 α -P levels both in vitro and in vivo. (A) Schematic showing the GFAP-empty and GFAP-AhuGADD34 lentiviral constructs. (B) GFP staining in astrocytes transduced with either LV-GFAP-empty or LV-GFAP- Δ huGADD34 for 7 days. Scale bar, 50 µm. (**C**) Primary astrocytes, transduced with LV-GFAP-empty or LV-GFAP-ΔhuGADD34 for 7 days, were treated with 300 nM Tg for 2 hours. Astrocytes expressing Δ huGADD34 showed increased protein synthesis rates and lower levels of eIF2 α -P on Tg treatment compared to astrocytes expressing GFP alone. Quantification shown in (**D**). Bar graphs show mean \pm SEM. *p < 0.05, **p < 0.01, one-way ANOVA. n = 3 biological replicates. (E) Representative images of GFP staining in the hippocampus of prion-inoculated mice injected with LV-GFAP-ΔhuGADD34. GFP staining co-localised with GFAP+ astrocytes. The over-expression of astrocytic ΔhuGADD34 substantially reduced the levels of astrocytosis compared to un-injected prion-inoculated mice. Scale bar, 50 μ m, zoomed panel, 20 μ m. (F) Western blot analysis of eIF2 α -P in NBH, prion, prion + LV-GFAP-empty and prion + LV-GFAP-ΔhuGADD34 mice. The over-expression of ΔhuGADD34 significantly reduced the levels of eIF2 α -P, as quantified in (G). Bar graph shows mean \pm SEM. *p <0.05, Student's t-test. n = 3 mice per condition. (H) Transcript levels of $\Delta huGADD34$ in prioninoculated mice injected with either LV-GFAP-empty or LV-GFAP-ΔhuGADD34. ΔhuGADD34 was only detected in LV-GFAP- Δ huGADD34-treated mice. ***p <0.001, Student's t-test. n = 5 mice per condition. (I) The astrocytic expression of ΔhuGADD34 significantly reduced the mRNA levels of the UPR-reactivity markers C3, Cxcl10, Lcn2 and Vim at 10 w.p.i., as analysed by qPCR. *p <0.05 **p <0.01, Student's t-test. n = 5 mice per condition. (J) Neuronal or astrocytic modulation of PERK-eIF2 α both significantly prolonged survival. LV-CAMKII-empty = 9 mice, LV-CAMKII-ΔhuGADD34 = 12 mice, LV-GFAP-empty = 6 mice, LV-GFAP- Δ huGADD34 = 11 mice. **p <0.01, ***p <0.001, Mantel-Cox test. (**K**) Astrocytic ΔhuGADD34 does not affect the levels of total PrP or proteinase K-resistant PrP^{Sc}.

			Biological replicate 1				ogical rep			ogical rep		Average			
Identified Proteins	Accession Number	Molecular Weight	vehicle	Tg	Tg + GSK	vehicle	Tg	Tg + GSK	vehicle	Tg	Tg + GSK	vehicle	Tg	Tg + GSP	
14-3-3 protein epsilon OS=Mus musculus OX=10090 GN=Ywhae PE=1 SV=1 14-3-3 protein eta OS=Mus musculus OX=10090 GN=Ywhah PE=1 SV=2	1433E_MOUSE 1433F MOUSE	29 kDa 28 kDa	1.00 1.00	1.63 1.25	4.88 5.00	1.00 1.00	0.74	1.63 2.40	1.00 1.00	0.67 0.75	0.81	1.00 1.00	1.01 1.00	2.44 2.66	
14-3-3 protein eta US=mus musculus UX=10090 GN=Ywhan PE=1 SV=2 14-3-3 protein gamma OS=Mus musculus OX=10090 GN=Ywhag PE=1 SV=2	1433F_MOUSE 1433G MOUSE	28 kDa 28 kDa	1.00	1.25	3.60	1.00	1.00	1.83	1.00	0.75	0.58	1.00	1.00	2.00	
14-3-3 protein theta (Fragment) OS=Mus musculus OX=10090 GN=1 whag PE=1 SV=2	F6VW30_MOUSE (+3)	26 kDa 34 kDa	1.00	1.40	6.00	1.00	0.70	1.80	1.00	0.84	0.69	1.00	0.98	2.02	
14-3-3 protein zeta/delta OS=Mus musculus OX=10090 GN=Ywhaz PE=1 SV=1	1433Z MOUSE	28 kDa	1.00	1.50	3.38	1.00	0.64	1.50	1.00	0.79	0.58	1.00	0.98	1.82	
6-phosphogluconate dehydrogenase, decarboxylating OS=Mus musculus OX=10090 GN=Pgd PE=1 SV=3	6PGD MOUSE	53 kDa	-	3.00	12.00	1.00	1.50	3.00	1.00	1.67	1.67	1.00	2.06	5.56	
Alpha-2-macroalobulin-P OS-Hus musculus OX=10090 GN=A2m PE=2 SV=2	A2MG MOUSE	164 kDa	1.00	0.16	0.47	1.00	0.93	0.97	1.00	0.61	0.61	1.00	0.57	0.69	
Alpha-enolase OS=Mus musculus OX=10090 GN=Eno1 PE=1 SV=3	ENOA_MOUSE	47 kDa	1.00	1.57	3.86	1.00	0.75	1.38	1.00	0.95	0.77	1.00	1.09	2.00	
Amyloid-beta A4 protein OS=Mus musculus OX=10090 GN=App PE=1 SV=1	A0A2I3BPT1_MOUSE (+3)	83 kDa	1.00	1.00	1.00	1.00	0.59	0.94	1.00	0.83	1.33	1.00	0.81	1.09	
Annexin A2 OS=Mus musculus OX=10090 GN=Anxa2 PE=1 SV=2	ANXA2 MOUSE	39 kDa	1.00	1.75	2.75	1.00	1.00	1.15	1.00	0.82	0.73	1.00	1.19	1.54	
Annexin A3 OS=Mus musculus OX=10090 GN=Anxa3 PE=1 SV=4	ANXA3 MOUSE	36 kDa	1.00	3.00	6.50	1.00	0.67	1.22	1.00	0.94	0.69	1.00	1.53	2.80	
Annexin A5 OS=Mus musculus OX=10090 GN=Anxa5 PE=1 SV=1	ANXA5_MOUSE	36 kDa	1.00	6.00	19.00	1.00	0.67	1.17	1.00	0.65	0.59	1.00	2.44	6.92	
Apolipoprotein E OS=Mus musculus OX=10090 GN=Apoe PE=1 SV=2	APOE_MOUSE	36 kDa	1.00	1.00	3.25	1.00	0.14	0.93	1.00	0.53	0.53	1.00	0.56	1.57	
Arginine-rich, mutated in early stage tumors, isoform CRA_b OS=Mus musculus OX=10090 GN=Manf PE=1 SV=1	Q3TMX5_MOUSE (+1)	20 kDa	-	5.00	2.00	-	3.00	3.00	-	3.00	1.00	-	3.67	2.00	
Basement membrane-specific heparan sulfate proteoglycan core protein OS=Mus musculus OX=10090 GN=Hspg2 PE=1 SV=1	B1B0C7_MOUSE (+1)	469 kDa	1.00	0.12	0.94	1.00	0.64	0.93	1.00	0.74	0.74	1.00	0.50	0.87	
Beta-actin-like protein 2 OS=Mus musculus OX=10090 GN=Actbl2 PE=1 SV=1	ACTBL_MOUSE	42 kDa	1.00	1.20	4.20	1.00	0.75	0.80	1.00	0.83	0.92	1.00	0.93	1.97	
Biglycan OS=Mus musculus OX=10090 GN=Bgn PE=1 SV=1	PGS1_MOUSE	42 kDa	1.00	0.29	0.57	1.00	0.84	1.05	1.00	0.56	0.44	1.00	0.56	0.69	
Brain acid soluble protein 1 OS=Mus musculus OX=10090 GN=Basp1 PE=1 SV=3	BASP1_MOUSE	22 kDa	-	3.00	4.00	1.00	0.90	1.10	1.00	1.00	1.75	1.00	1.63	2.28	
Caldesmon 1 OS=Mus musculus OX=10090 GN=Cald1 PE=1 SV=1	E9Q0M9_MOUSE	62 kDa	1.00	2.50	6.50	1.00	0.44	1.11	1.00	1.67	3.00	1.00	1.54	3.54	
Calreticulin OS=Mus musculus OX=10090 GN=Calr PE=1 SV=1	CALR_MOUSE	48 kDa	1.00	3.25	4.00	1.00	1.13	1.13	1.00	1.20	0.93	1.00	1.86	2.02	
Calumenin OS=Mus musculus OX=10090 GN=Calu PE=1 SV=1	CALU_MOUSE	37 kDa	-	6.00	8.00	1.00	0.56	0.56	1.00	1.17	1.17	1.00	2.57	3.24	
Carboxypeptidase E OS=Mus musculus OX=10090 GN=Cpe PE=1 SV=2	CBPE_MOUSE	53 kDa	1.00	0.60	1.70	1.00	0.48	0.77	1.00	0.58	0.84	1.00	0.55	1.11	
Cathepsin B OS=Mus musculus OX=10090 GN=Ctsb PE=1 SV=2	CATB_MOUSE	37 kDa	1.00	1.13	2.00	1.00	0.47	0.93	1.00	0.65	0.59	1.00	0.75	1.17	
Cathepsin Z OS=Mus musculus OX=10090 GN=Ctsz PE=1 SV=1	CATZ_MOUSE	34 kDa	1.00	1.50	2.00	1.00	0.67	1.00	1.00	1.00	1.50	1.00	1.06	1.50	
Cluster of Isoform 2 of Tropomyosin beta chain OS=Mus musculus OX=10090 GN=Tpm2 (sp P58774-2 TPM2_MOUSE)	sp P58774-2 TPM2_MOUSE [2]	33 kDa	1.00	1.86	3.00	1.00	0.65	0.76	1.00	0.62	0.71	1.00	1.04	1.49	
Cofilin-1 OS=Mus musculus OX=10090 GN=Cfl1 PE=1 SV=3	COF1_MOUSE	19 kDa	1.00	7.00	15.00	1.00	3.00	6.50	1.00	0.75	1.00	1.00	3.58	7.50	
Collagen alpha-1(I) chain OS=Mus musculus OX=10090 GN=Col1a1 PE=1 SV=4 Collagen alpha-1(IV) chain OS=Mus musculus OX=10090 GN=Col4a1 PE=1 SV=4	sp P11087 CO1A1_MOUSE CO4A1 MOUSE	138 kDa 161 kDa	1.00 1.00	0.67	1.00 1.60	1.00 1.00	0.65	0.86	1.00 1.00	0.61 1.25	0.58	1.00	0.64	0.81	
Collagen alpha-1(IV) chain OS=Mus musculus OX=10090 GN=Col4a1 PE=1 SV=4 Collagen alpha-1(V) chain OS=Mus musculus OX=10090 GN=Col5a1 PE=1 SV=2	CO5A1 MOUSE	184 kDa	1.00	1.00	1.60	1.00	0.80	0.67	1.00	0.67	0.67	1.00	0.95	0.89	
Collagen alpha-1(v) chain OS=Mus musculus OX=10090 GN=Colsa1 PE=1 SV=2 Collagen alpha-2(l) chain OS=Mus musculus OX=10090 GN=Col1a2 PE=1 SV=2	CO1A2 MOUSE	130 kDa	1.00	0.39	0.72	1.00	0.33	1.00	1.00	1.00	1.00	1.00	0.67	0.89	
Collagen alpha-2(IV) chain OS=Mus musculus OX=10090 GN=Col4a2 PE=1 SV=2	CO4A2 MOUSE	167 kDa	1.00	0.39	0.91	1.00	0.88	0.77	1.00	1.25	1.00	1.00	0.68	0.89	
Collagen alpha-2(V) chain OS=Mus musculus OX=10090 GN=Colfa2 PE=1 SV=4 Collagen alpha-2(V) chain OS=Mus musculus OX=10090 GN=Col5a2 PE=1 SV=1	CO5A2_MOUSE	145 kDa	1.00	0.18	1.29	1.00	0.62	1.09	1.00	1.25	1.00	1.00	0.58	1.12	
Complement C3 OS=Mus musculus OX=10090 GN=C3 PE=1 SV=3	spIP01027ICO3 MOUSE	186 kDa	1.00	0.00	3.00	1.00	0.45	0.70	1.00	2.40	1.00	1.00	0.95	1.57	
Creatine kinase B-type OS=Mus musculus OX=10090 GN=Ckb PE=1 SV=1	KCRB MOUSE	43 kDa	1.00	2.75	7.50	1.00	0.60	1.00	1.00	1.00	1.04	1.00	1.45	3.18	
Cystatin-C OS=Mus musculus OX=10090 GN=Cst3 PE=1 SV=2	CYTC_MOUSE	16 kDa	1.00	0.75	2.00	1.00	0.85	0.92	1.00	1.20	1.20	1.00	0.93	1.37	
EGF-containing fibulin-like extracellular matrix protein 1 OS=Mus musculus OX=10090 GN=Efemp1 PE=1 SV=1	FBLN3_MOUSE	55 kDa	1.00	0.00	0.67	1.00	0.00	0.40	1.00	0.25	0.75	1.00	0.08	0.61	
EGF-containing fibulin-like extracellular matrix protein 2 OS=Mus musculus OX=10090 GN=Efemp2 PE=1 SV=1	FBLN4_MOUSE (+1)	49 kDa	1.00	0.00	1.00	1.00	0.54	0.69	1.00	0.60	0.80	1.00	0.38	0.83	
Elongation factor 1-alpha 1 OS=Mus musculus OX=10090 GN=Eef1a1 PE=1 SV=3	EF1A1 MOUSE	50 kDa	1.00	1.00	2.40	1.00	1.00	1.20	1.00	0.83	0.75	1.00	0.94	1.45	
Endoplasmic reticulum chaperone BiP OS=Mus musculus OX=10090 GN=Hspa5 PE=1 SV=3	BIP MOUSE	72 kDa	1.00	2.07	2.43	1.00	2.05	1.48	1.00	1.38	1.12	1.00	1.83	1.67	
Endoplasmin OS=Mus musculus OX=10090 GN=Hsp90b1 PE=1 SV=2	ENPL_MOUSE	92 kDa	1.00	5.75	5.00	1.00	1.89	1.37	1.00	1.68	1.11	1.00	3.11	2.49	
Extracellular matrix protein 1 OS=Mus musculus OX=10090 GN=Ecm1 PE=1 SV=2	sp Q61508 ECM1_MOUSE	63 kDa	1.00	0.40	1.20	1.00	0.25	0.50	1.00	0.50	0.67	1.00	0.38	0.79	
Ezrin OS=Mus musculus OX=10090 GN=Ezr PE=1 SV=3	EZRI_MOUSE	69 kDa	1.00	1.20	2.40	1.00	0.43	0.79	1.00	0.86	1.00	1.00	0.83	1.40	
Farnesyl pyrophosphate synthase OS=Mus musculus OX=10090 GN=Fdps PE=1 SV=1	FPPS_MOUSE	41 kDa	1.00	4.00	8.00	1.00	0.43	1.29	1.00	0.71	0.71	1.00	1.71	3.33	
Fibromodulin OS=Mus musculus OX=10090 GN=Fmod PE=2 SV=1	FMOD_MOUSE	43 kDa	1.00	1.00	2.67	1.00	0.31	0.92	1.00	0.33	0.56	1.00	0.55	1.38	
Fibronectin OS=Mus musculus OX=10090 GN=Fn1 PE=1 SV=1	A0A087WR50_MOUSE	263 kDa	1.00	0.45	1.03	1.00	0.70	0.89	1.00	0.85	0.77	1.00	0.67	0.89	
Fibulin-5 OS=Mus musculus OX=10090 GN=FbIn5 PE=1 SV=1	A0A1Y7VJW9_MOUSE (+1)	52 kDa	1.00	0.33	1.33	1.00	0.53	0.63	1.00	0.22	0.22	1.00	0.36	0.73	
Filamin-B OS=Mus musculus OX=10090 GN=FInb PE=1 SV=3	FLNB_MOUSE	278 kDa	1.00	0.40	4.20	1.00	0.71	1.05	1.00	0.94	0.89	1.00	0.69	2.05	
Filamin, alpha OS=Mus musculus OX=10090 GN=FIna PE=1 SV=1	B7FAU9_MOUSE (+2)	280 kDa	1.00	0.88	3.53	1.00	0.69	1.24	1.00	1.14	1.08	1.00	0.90	1.95	
Follistatin-related protein 1 OS=Mus musculus OX=10090 GN=FstI1 PE=1 SV=2	FSTL1_MOUSE	35 kDa	1.00	1.75	1.75	1.00	0.90	1.05	1.00	0.50	0.67	1.00	1.05	1.15	
Fructose-bisphosphate aldolase A OS=Mus musculus OX=10090 GN=Aldoa PE=1 SV=2	ALDOA_MOUSE	39 kDa	1.00	2.50	6.75	1.00	0.68	1.05	1.00	0.75	0.96	1.00	1.31	2.92	
Galectin-1 OS=Mus musculus OX=10090 GN=Lgals1 PE=1 SV=3	LEG1_MOUSE	15 kDa	1.00	1.50	3.50	1.00	1.00	1.67	1.00	1.67	1.33	1.00	1.39	2.17	
Galectin-3-binding protein OS=Mus musculus OX=10090 GN=Lgals3bp PE=1 SV=1	LG3BP_MOUSE	64 kDa	1.00	0.29	0.71	1.00	0.50	0.50	1.00	0.50	1.00	1.00	0.43	0.74	
Glucose-6-phosphate isomerase OS=Mus musculus OX=10090 GN=Gpi PE=1 SV=4	G6PI_MOUSE	63 kDa	1.00	9.00	17.00	1.00	0.60	1.27	1.00	1.31	1.23	1.00	3.64	6.50	
Glutathione S-transferase Mu 1 OS=Mus musculus OX=10090 GN=Gstm1 PE=1 SV=2	GSTM1_MOUSE	26 kDa	1.00	0.60	3.60	1.00	0.83	1.17	1.00	1.00	1.09	1.00	0.81	1.95	
Glutathione S-transferase Mu 2 OS=Mus musculus OX=10090 GN=Gstm2 PE=1 SV=2	GSTM2_MOUSE	26 kDa	1.00	0.33	4.67	1.00	1.00	1.60	1.00	1.33	1.67	1.00	0.89	2.64	
Glypican-4 OS=Mus musculus OX=10090 GN=Gpc4 PE=1 SV=2	GPC4_MOUSE	63 kDa	1.00	0.78	1.67	1.00	0.69	0.96	1.00	0.50	0.70	1.00	0.66	1.11	
Growth arrest-specific protein 6 OS=Mus musculus OX=10090 GN=Gas6 PE=2 SV=2	GAS6_MOUSE	75 kDa	1.00	0.00	0.60	1.00	0.09	0.18	1.00	0.00	0.00	1.00	0.03	0.26	
Heat shock cognate 71 kDa protein OS=Mus musculus OX=10090 GN=Hspa8 PE=1 SV=1	HSP7C_MOUSE	71 kDa	1.00	0.93	2.36	1.00	0.88	1.21	1.00	0.88	0.97	1.00	0.90	1.51	
Heat shock protein HSP 90-alpha OS=Mus musculus OX=10090 GN=Hsp90aa1 PE=1 SV=4	HS90A_MOUSE	85 kDa	1.00	1.00	2.63	1.00	0.45	0.90	1.00	1.09	1.04	1.00	0.85	1.52	
Heat shock protein HSP 90-beta OS=Mus musculus OX=10090 GN=Hsp90ab1 PE=1 SV=3	HS90B_MOUSE	83 kDa	1.00	1.40	2.50	1.00	0.47	0.94	1.00	1.00	1.00	1.00	0.96	1.48	
Insulin-like growth factor-binding protein 2 OS=Mus musculus OX=10090 GN=Igfbp2 PE=2 SV=2	IBP2_MOUSE	33 kDa	1.00	1.18	1.88	1.00	0.62	0.87	1.00	0.56	0.70	1.00	0.78	1.15	
Insulin-like growth factor-binding protein 3 OS=Mus musculus OX=10090 GN=Igfbp3 PE=2 SV=2	IBP3_MOUSE	32 kDa	1.00	0.50	1.00	1.00	0.57	1.29	1.00	0.80	0.80	1.00	0.62	1.03	
Insulin-like growth factor-binding protein 5 OS=Mus musculus OX=10090 GN=Igfbp5 PE=1 SV=1	IBP5_MOUSE	30 kDa	1.00	0.50	2.00	1.00	0.44	1.22	1.00	1.00	1.50	1.00	0.65	1.57	
Isoform 2 of A-kinase anchor protein 12 OS=Mus musculus OX=10090 GN=Akap12	sp Q9WTQ5-2 AKA12_MOUSE	170 kDa	1.00	2.20	4.20	1.00	0.63	1.16	1.00	1.00	1.04	1.00	1.28	2.13	
	IOOEDLA AIOOTNIA MOURSE	400 10-	4 0 0	0.00	0.00	4.00	0.75	0.75							
Isoform 2 of Calsyntenin-1 OS=Mus musculus OX=10090 GN=Clstn1	sp Q9EPL2-2 CSTN1_MOUSE	108 kDa	1.00	0.20	0.60	1.00	0.75	0.75	1.00	0.63	0.75	1.00	0.53	0.70	
	splQ9EPL2-2 CSTN1_MOUSE splP37889-2 FBLN2_MOUSE (+1) splP13020-2 GELS_MOUSE	108 kDa 126 kDa 81 kDa	1.00 1.00	0.20 0.50 3.00	0.60 0.00 19.00	1.00 1.00 1.00	0.75 0.47 3.00	0.75 0.53 12.00	1.00 1.00 1.00	0.63 0.29 0.78	0.75 0.71 1.33	1.00 1.00 1.00	0.53 0.42 2.26	0.70	

								Normalised	spectral counts	S						
					Biological replicate 1 Biological replicate 2					Biological replicate3				Average		
Identified Proteins	Accession Number	Molecular Weight	vehicle	Tg	Tg + GSK	vehicle	Tg	Tg + GSK	vehicle	Tg	Tg + GSK	vehicle	Tg	Tg + GSK		
Isoform 2 of Glial fibrillary acidic protein OS=Mus musculus OX=10090 GN=Gfap	sp P03995-2 GFAP_MOUSE	49 kDa 60 kDa	1.00	2.00	8.50	1.00	1.33	1.17 1.50	1.00	0.67	0.67	1.00	1.33 2.93	3.44		
Isoform 2 of Glucosidase 2 subunit beta OS=Mus musculus OX=10090 GN=Prkcsh Isoform 2 of Prolvl 4-hydroxylase subunit alpha-1 OS=Mus musculus OX=10090 GN=P4ha1	sp O08795-2 GLU2B_MOUSE (+1) sp Q60715-2 P4HA1_MOUSE	60 kDa 61 kDa	1.00	5.00 9.00	3.00	1.00 1.00	2.00	3.33	1.00 1.00	1.80	1.60	1.00	2.93	2.03 5.56		
Isoform 2 of Prolyn 4-hydroxylase subunit alpha-1 OS=Mus musculus OX=10090 GN=P4ha t Isoform 2 of Tropomyosin alpha-1 chain OS=Mus musculus OX=10090 GN=Tpm1	sp P58771-2 TPM1_MOUSE	33 kDa	1.00	1.40	3.00	1.00	0.70	0.87	1.00	0.78	0.73	1.00	0.96	1.53		
Isoform 2 of Tropomyosin alpha-3 chain OS=Mus musculus OX=10090 GN=1pm1	sp[P21107-2]TPM3_MOUSE	29 kDa	1.00	1.40	3.44	1.00	0.70	0.87	1.00	0.78	0.73	1.00	1.12	1.55		
Isoform M1 of Pyruvate kinase PKM OS=Mus musculus OX=10090 GN=1pms	spiP52480-2 KPYM_MOUSE	29 kDa 58 kDa	1.00	0.70	2.90	1.00	0.72	1.27	1.00	1.28	1.28	1.00	0.95	1.75		
Isoform Short of 14-3-3 protein beta/alpha OS=Mus musculus OX=10090 GN=Ywhab	splQ9CQV8-2 1433B MOUSE (+1)	28 kDa	1.00	2.25	6.00	1.00	0.87	1.27	1.00	0.69	0.56	1.00	1.23	2.69		
L-lactate dehydrogenase OS=Mus musculus OX=10090 GN=Ldha PE=1 SV=1	A0A1B0GSX0_MOUSE (+2)	40 kDa	1.00	1.25	2.25	1.00	0.47	0.93	1.00	0.82	0.76	1.00	0.85	1.32		
Latent-transforming growth factor beta-binding protein 2 OS=Mus musculus OX=10090 GN=Ltbp2 PE=1 SV=1	E9QNQ3 MOUSE	196 kDa	1.00	0.40	0.80	1.00	0.47	0.86	1.00	0.62	0.33	1.00	0.55	0.66		
Lill and SH3 domain protein 1 OS=Mus musculus OX=10090 GN=Last1 PE=1 SV=1	LASP1 MOUSE	30 kDa	-	3.00	4.00	1.00	0.33	1.33	1.00	1.00	1.67	1.00	1.44	2.33		
Low density lipoprotein receptor-related protein 1 OS=Muse musculus OX=10090 GN=Lrp1 PE=1 SV=1	A0A0R4J0I9 MOUSE (+1)	505 kDa	1.00	0.18	0.76	1.00	0.58	1.12	1.00	0.74	0.74	1.00	0.50	0.87		
Low-density ipoprotein receptor-related protein 2 OS=Mus musculus OX=10090 GN=Lrp2 PE=1 SV=1	LRP2_MOUSE	519 kDa	1.00	0.00	0.75	1.00	0.82	1.47	1.00	1.08	0.83	1.00	0.64	1.02		
Macrophage colony-stimulating factor 1 OS=Mus musculus OX=10090 GN=Cs11 PE=1 SV=2	spIP07141ICSF1 MOUSE	61 kDa	1.00	1.00	1.00	1.00	0.83	1.00	1.00	0.67	1.00	1.00	0.83	1.00		
Malate dehydrogenase, cytoplasmic OS=Mus musculus OX=10090 GN=Mdh1 PE=1 SV=3	MDHC MOUSE	37 kDa	1.00	3.00	12.00	1.00	0.50	1.10	1.00	1.14	1.14	1.00	1.55	4.75		
Malate dehydrogenase, mitochondrial OS=Mus musculus OX=10090 GN=Mdh2 PE=1 SV=3	MDHM MOUSE	36 kDa	1.00	2.50	6.50	1.00	0.67	0.83	1.00	1.11	0.89	1.00	1.43	2.74		
Metalloproteinase inhibitor 2 OS=Mus musculus OX=10090 GN=Timp2 PE=1 SV=1	Q6PI17 MOUSE (+1)	24 kDa	1.00	0.67	1.33	1.00	0.56	0.67	1.00	0.33	0.42	1.00	0.52	0.81		
Moesin OS=Mus musculus OX=10090 GN=Msn PE=1 SV=3	MOES_MOUSE	68 kDa	1.00	1.33	4.00	1.00	0.44	1.00	1.00	0.87	1.00	1.00	0.88	2.00		
Myosin-9 OS=Mus musculus OX=10090 GN=Myh9 PE=1 SV=4	MYH9_MOUSE	226 kDa	1.00	5.00	38.00	1.00	0.83	1.24	1.00	1.24	1.12	1.00	2.36	13.45		
N(G).N(G)-dimethylarginine dimethylaminohydrolase 1 OS=Mus musculus OX=10090 GN=Ddah1 PE=1 SV=3	DDAH1_MOUSE	31 kDa	-	1.00	1.75	1.00	1.00	1.00	1.00	1.20	0.80	1.00	2.07	2.93		
Nestin OS=Mus musculus OX=10090 GN=Nes PE=1 SV=1	sp Q6P5H2 NEST_MOUSE	207 kDa	1.00	1.00	3.40	1.00	0.17	0.61	1.00	1.11	1.04	1.00	0.76	1.68		
Neurocan core protein OS=Mus musculus OX=10090 GN=Ncan PE=1 SV=1	A0A0R4IZX5_MOUSE (+1)	137 kDa	1.00	0.60	1.60	1.00	1.00	1.00	1.00	0.50	1.00	1.00	0.70	1.20		
Nidogen-2 OS=Mus musculus OX=10090 GN=Nid2 PE=1 SV=2	NID2_MOUSE	154 kDa	1.00	0.20	1.20	1.00	0.47	0.53	1.00	0.63	0.63	1.00	0.43	0.78		
Nucleobindin-1 OS=Mus musculus OX=10090 GN=Nucb1 PE=1 SV=2	NUCB1_MOUSE	53 kDa	1.00	3.25	2.75	1.00	0.75	0.94	1.00	0.58	0.75	1.00	1.53	1.48		
Nucleoside diphosphate kinase OS=Mus musculus OX=10090 GN=Gm20390 PE=3 SV=1	E9PZF0_MOUSE	30 kDa	1.00	1.33	3.67	1.00	0.86	1.14	1.00	1.40	1.00	1.00	1.20	1.94		
Peptidyl-prolyl cis-trans isomerase A OS=Mus musculus OX=10090 GN=Ppia PE=1 SV=2	PPIA_MOUSE	18 kDa	1.00	1.50	4.00	1.00	0.78	1.44	1.00	1.83	1.83	1.00	1.37	2.43		
Peroxiredoxin-1 OS=Mus musculus OX=10090 GN=Prdx1 PE=1 SV=1	PRDX1_MOUSE	22 kDa	1.00	1.00	2.50	1.00	1.00	1.56	1.00	1.14	1.00	1.00	1.05	1.69		
Peroxiredoxin-2 OS=Mus musculus OX=10090 GN=Prdx2 PE=1 SV=3	PRDX2_MOUSE	22 kDa	1.00	1.00	2.33	1.00	1.00	1.60	1.00	1.25	1.00	1.00	1.08	1.64		
Phosphoglycerate kinase 1 OS=Mus musculus OX=10090 GN=Pgk1 PE=1 SV=4	-	45 kDa	-	5.00	14.00	1.00	1.40	2.60	1.00	1.33	1.33	1.00	2.58	5.98		
Pigment epithelium-derived factor OS=Mus musculus OX=10090 GN=Serpinf1 PE=1 SV=2	PEDF_MOUSE	46 kDa	1.00	0.86	1.57	1.00	0.47	0.80	1.00	0.42	0.58	1.00	0.58	0.98		
Plasminogen activator inhibitor 1 OS=Mus musculus OX=10090 GN=Serpine1 PE=1 SV=1	G5E899_MOUSE	45 kDa	1.00	0.25	2.75	1.00	0.44	0.89	1.00	0.64	0.71	1.00	0.45	1.45		
Prosaposin OS=Mus musculus OX=10090 GN=Psap PE=1 SV=1	E9PZ00_MOUSE (+4)	61 kDa	1.00	0.71	2.86	1.00	0.53	1.13	1.00	0.58	0.83	1.00	0.61	1.61		
Proteasome subunit alpha type-1 OS=Mus musculus OX=10090 GN=Psma1 PE=1 SV=1	PSA1_MOUSE	30 kDa	1.00	3.00	10.00	1.00	0.67	0.83	1.00	0.86	0.71	1.00	1.51	3.85		
Proteasome subunit alpha type-6 OS=Mus musculus OX=10090 GN=Psma6 PE=1 SV=1	PSA6_MOUSE	27 kDa	1.00	3.00	6.00	1.00	0.67	1.00	1.00	1.50	1.25	1.00	1.72	2.75		
Proteasome subunit alpha type-7 OS=Mus musculus OX=10090 GN=Psma7 PE=1 SV=1	PSA7_MOUSE	28 kDa	1.00	1.50	4.00	1.00	1.00	0.83	1.00	0.78	0.89	1.00	1.09	1.91		
Protein disulfide-isomerase A3 OS=Mus musculus OX=10090 GN=Pdia3 PE=1 SV=2	PDIA3_MOUSE	57 kDa 72 kDa	1.00 1.00	3.33	5.17 14.00	1.00	1.32 1.40	1.18	1.00	1.30	0.96	1.00	1.99	2.44 5.58		
Protein disulfide-isomerase A4 OS=Mus musculus OX=10090 GN=Pdia4 PE=1 SV=1 Protein disulfide-isomerase A6 OS=Mus musculus OX=10090 GN=Pdia6 PE=1 SV=1	A0A0R4J0Z1_MOUSE (+1) Q3TML0_MOUSE	72 kDa 49 kDa	1.00	7.00	9.00	1.00 1.00	1.40	1.60	1.00 1.00	2.13 1.80	1.13	1.00	3.51 3.49	5.58 4.09		
Protein disulfide-isomerase A6 OS=Mus musculus OX=10090 GN=Pdia6 PE=1 SV=1 Protein disulfide-isomerase OS=Mus musculus OX=10090 GN=Pdia6 PE=1 SV=2	PDIA1 MOUSE	49 kDa 57 kDa	1.00	1.40	9.00	1.00	1.67	1.67	1.00	1.80	0.81	1.00	3.49	4.09		
Purine nucleoside phosphorylase OS=Mus musculus OX=10090 GN=Php PE=1 SV=2	PNPH MOUSE (+1)	32 kDa	1.00	5.00	14.00	1.00	0.00	0.88	1.00	1.29	1.29	1.00	2.10	5.39		
Rab GDP dissociation inhibitor alpha OS=Mus musculus OX=10090 GN=Php PE=1 SV=2	GDIA MOUSE	52 kDa 51 kDa	1.00	3.00	10.00	1.00	0.56	1.67	1.00	1.14	1.43	1.00	1.57	4.37		
Rab GDP dissociation inhibitor beta OS=Mus musculus OX=10090 GN=Gdi2 PE=1 SV=3	splQ61598 GDIB MOUSE	51 kDa	1.00	2.50	10.00	1.00	0.56	1.20	1.00	1.14	1.43	1.00	1.57	4.37		
Radixin OS=Mus musculus OX=10090 GN=Rdx PE=1 SV=3	RADI MOUSE	69 kDa	1.00	1.25	3.25	1.00	0.07	1.11	1.00	1.09	1.09	1.00	0.93	1.82		
Receptor-type tyrosine-protein phosphatase zeta OS=Mus musculus OX=10000 GN=Ptprz1 PE=1 SV=1	PRPTZ MOUSE	254 kDa	1.00	0.57	1.00	1.00	0.83	1.06	1.00	0.71	0.57	1.00	0.71	0.88		
Serine/threenine-protein phosphatase 2A 65 KDa regulatory subunit A alpha isoform OS=Mus Musculus OX=10090 GN=Ppp2r1a PE=1 SV=		65 kDa	-	3.00	4.00	1.00	0.67	2.00	1.00	1.00	1.40	1.00	1.56	2.47		
SPARC OS=Mus musculus OX=10090 GN=Sparc PE=1 SV=1	A0A1L1SSH9 MOUSE (+2)	38 kDa	1.00	1.05	1.52	1.00	0.71	0.71	1.00	0.57	0.48	1.00	0.77	0.90		
SPARC-like protein 1 OS=Mus musculus OX=10090 GN=Sparc 1 PE=1 SV=3	SPRL1 MOUSE	72 kDa	1.00	0.00	0.33	1.00	0.00	0.18	1.00	1.00	0.67	1.00	0.33	0.39		
Tenascin OS=Mus musculus OX=10090 GN=Tnc PE=1 SV=1	spiQ80YX1/TENA MOUSE	232 kDa	1.00	0.54	1.46	1.00	1.04	0.92	1.00	0.84	0.80	1.00	0.81	1.06		
Thioredoxin domain-containing protein 5 OS=Mus musculus OX=10090 GN=Txndc5 PE=1 SV=1	E9PXX7 MOUSE (+1)	39 kDa	1.00	7.00	13.00	1.00	1.86	1.86	1.00	1.33	1.00	1.00	3.40	5.29		
Transgelin OS=Mus musculus OX=10090 GN=TagIn PE=1 SV=3	TAGL MOUSE	23 kDa	1.00	2.00	4.00	1.00	0.46	1.00	1.00	0.87	0.73	1.00	1.11	1.91		
Transitional endoplasmic reticulum ATPase OS=Mus musculus OX=10090 GN=Vcp PE=1 SV=4	TERA MOUSE	89 kDa	1.00	1.13	3.25	1.00	1.00	1.63	1.00	1.09	1.18	1.00	1.07	2.02		
Transketolase OS=Mus musculus OX=10090 GN=Tkt PE=1 SV=1	TKT_MOUSE	68 kDa	1.00	2.33	7.67	1.00	0.88	1.25	1.00	1.06	1.00	1.00	1.42	3.31		
Triosephosphate isomerase OS=Mus musculus OX=10090 GN=Tpi1 PE=1 SV=4	TPIS_MOUSE	32 kDa	-	4.00	13.00	1.00	1.00	1.75	1.00	1.75	1.25	1.00	2.25	5.33		
Tropomyosin alpha-4 chain OS=Mus musculus OX=10090 GN=Tpm4 PE=1 SV=3	TPM4_MOUSE	28 kDa	1.00	2.60	4.60	1.00	0.83	0.92	1.00	0.60	0.87	1.00	1.34	2.13		
Tubulin beta-2A chain OS=Mus musculus OX=10090 GN=Tubb2a PE=1 SV=1	TBB2A_MOUSE	50 kDa	1.00	1.20	2.60	1.00	0.59	0.88	1.00	1.24	1.18	1.00	1.01	1.55		
Tubulin beta-4B chain OS=Mus musculus OX=10090 GN=Tubb4b PE=1 SV=1	TBB4B_MOUSE	50 kDa	1.00	1.00	2.50	1.00	0.60	0.80	1.00	1.46	1.46	1.00	1.02	1.59		
Tubulin beta-5 chain OS=Mus musculus OX=10090 GN=Tubb5 PE=1 SV=1	TBB5_MOUSE	50 kDa	1.00	1.00	2.83	1.00	0.69	1.00	1.00	1.12	1.12	1.00	0.94	1.65		
Vascular cell adhesion protein 1 OS=Mus musculus OX=10090 GN=Vcam1 PE=1 SV=1	Q3UPN1_MOUSE (+1)	81 kDa	1.00	0.67	0.67	1.00	1.00	1.50	1.00	1.33	1.33	1.00	1.00	1.17		
Vinculin OS=Mus musculus OX=10090 GN=Vcl PE=1 SV=4	VINC_MOUSE	117 kDa	1.00	0.50	8.50	1.00	1.00	1.68	1.00	1.28	1.24	1.00	0.93	3.81		
Vitamin K-dependent protein S OS=Mus musculus OX=10090 GN=Pros1 PE=2 SV=1	PROS_MOUSE	75 kDa	1.00	0.00	0.75	1.00	0.38	0.50	1.00	0.29	0.43	1.00	0.22	0.56		
WD repeat-containing protein 1 OS=Mus musculus OX=10090 GN=Wdr1 PE=1 SV=3	WDR1_MOUSE	66 kDa	1.00	0.75	3.00	1.00	0.59	1.12	1.00	1.13	1.27	1.00	0.82	1.79		

Table S1 (related to Figure 3). Proteins identified in conditioned media from vehicle-, Tg- and Tg+GSK2606414-treated astrocytes. Astrocyte conditioned media was concentrated and analysed by LC/MS. A protein was identified if it received \geq 99% confidence with \geq 3 unique peptides at 95% confidence in the vehicle- or Tg-treated condition. Only proteins meeting this criterion across all 3 biological replicates were included. Spectral counts were normalised to the vehicle-treated condition; normalised spectral counts from 3 biological replicates are shown.

Table S2 (related to STAR Methods). qPCR primer sequences used in this study.

Primer name	Sequence
Cxcl10 F	ATGACGGGCCAGTGAGAATG
Cxcl10 R	TCGTGGCAATGATCTCAACAC
Lcn2 F	CCACCACGGACTACAACCAG
Lcn2 R	TCCTTGGTTCTTCCATACAGGG
Serpina3n F	CCTGGAGGATGTCCTTTCAA
Serpina3n R	TTATCAGGAAAGGCCGATTG
Vim F	GCAGTATGAAAGCGTGGCT
Vim R	CTCCAGGGACTCGTTAGTGC
C3 F	AGCTTCAGGGTCCCAGCTAC
C3 R	GCTGGAATCTTGATGGAGACGC
ΔhuGADD34 F	GGACCCTGAGACTCCCCTAAA
ΔhuAGDD34 R	AGGAAATGGACAGTGACCTTCT